



**EARLY ASSISTED DISCHARGE WITH COMMUNITY NURSING  
FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
EXACERBATIONS: RESULTS OF A RANDOMISED  
CONTROLLED TRIAL**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001684
Article Type:	Research
Date Submitted by the Author:	18-Jun-2012
Complete List of Authors:	Utens, Cecile; Department of Respiratory Medicine, Catharina Hospital, ; CAPHRI School for Public Health and Primary Care, Maastricht University, Goossens, Lucas; Institute for Medical Technology Assessment, Erasmus University, Smeenk, Frank; Department of Respiratory Medicine, Catharina Hospital, Rutten-van Mólken, Maureen; Institute for Medical Technology Assessment, Erasmus University, van Vliet, Monique; Department of Respiratory Medicine, Atrium Medical Centre, Braken, Maria; Department of Staff nurses Nursing and Care, ZuidZorg, van Eijsden, Loes; Department of Health Care Policy, Meander Group Zuid-Limburg, van Schayck, Onno; CAPHRI School for Public Health and Primary Care, Maastricht University,
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	Chronic airways disease < THORACIC MEDICINE, PRIMARY CARE, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

**Title:**

Early assisted discharge with generic community nursing for Chronic Obstructive Pulmonary  
Disease exacerbations: results of a randomised controlled trial

Cecile MA Utens<sup>1,2</sup>, Lucas MA Goossens<sup>3</sup>, Frank WJM Smeenk<sup>1</sup>, Maureen PMH Rutten-van  
Mölken<sup>3</sup>, Monique van Vliet<sup>4</sup>, Maria W Braken<sup>5</sup>, Loes MGA van Eijnsden<sup>6</sup>, Onno CP van  
Schayck<sup>2</sup>

**Affiliations:**

<sup>1</sup>Department of Respiratory Medicine, Catharina-hospital Eindhoven, Eindhoven, the  
Netherlands, P.O. Box 1350 ZA Eindhoven, the Netherlands

<sup>2</sup>Department of General Practice, CAPHRI School for Public Health and Primary Care,  
Maastricht University, Maastricht, the Netherlands, P.O. box 616 6200 MD Maastricht, the  
Netherlands

Cecile MA Utens

PhD candidate

<sup>3</sup>Institute for Medical Health Technology Assessment, Erasmus University, Rotterdam, the  
Netherlands, P.O. box 1738 3000 DR Rotterdam, the Netherlands

Lucas MA Goossens

Researcher/ PhD candidate

<sup>1</sup>Department of Respiratory Medicine, Catharina-hospital Eindhoven, Eindhoven, the  
Netherlands, P.O. Box 1350 ZA Eindhoven, the Netherlands

Frank WJM Smeenk

1  
2  
3 Pulmonologist  
4  
5  
6

7 <sup>3</sup>Institute for Medical Health Technology Assessment, Erasmus University, Rotterdam, the  
8 Netherlands, P.O. box 1738 3000 DR Rotterdam, the Netherlands  
9

10  
11 Maureen PMH Rutten-van Mölken

12  
13  
14 Professor  
15  
16

17  
18 <sup>4</sup>Department of Respiratory Medicine, Atrium Medical Centre, Heerlen, the Netherlands, P.O.  
19 box 4446 6401 CZ Heerlen, the Netherlands  
20  
21

22  
23 Monique van Vliet

24  
25 Pulmonologist  
26  
27

28  
29 <sup>5</sup>Department of Staff nurses Nursing and Care, ZuidZorg, Veldhoven, the Netherlands, P.O.  
30 box 2160 5500 BD Veldhoven, the Netherlands  
31  
32

33  
34 Maria Braken

35  
36 Staff nurse  
37  
38

39  
40 <sup>6</sup>Department of Health Care Policy, Meander Group Zuid-Limburg, Heerlen, the Netherlands  
41 P.O. box 2690 6401 DD Heerlen, the Netherlands  
42  
43

44  
45 Loes van Eijnsden

46  
47 Policy officer  
48  
49

50  
51 <sup>2</sup>Department of General Practice, CAPHRI School for Public Health and Primary Care,  
52 Maastricht University, Maastricht, the Netherlands, P.O. box 616 6200 MD Maastricht, the  
53 Netherlands  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Onno CP van Schayck

4  
5 Professor

6  
7  
8  
9 **Corresponding author:**

10  
11 Cecile Utens

12  
13 Email: cecileutens@gmail.com

14  
15  
16  
17  
18 **Keywords:** Hospital at home; Early assisted discharge from hospital; Chronic Obstructive  
19 Pulmonary Disease; Community nursing, Randomised controlled trial  
20  
21  
22

23  
24  
25 **Abstract**

26  
27 **Objectives:** To determine effectiveness of early assisted discharge with home care provided  
28 by generic community nurses, compared to usual hospital care.  
29

30  
31 Design: Prospective, randomised controlled, multi-centre trial with 3 months follow-up.  
32

33  
34 **Setting:** Five hospitals and 3 home care organisations in the Netherlands.  
35

36  
37 **Participants:** Patients admitted to the hospital with an exacerbation of Chronic Obstructive  
38 Pulmonary Disease. Patients with no or limited improvement of respiratory symptoms and  
39 patients with severe unstable comorbidities, social problems or those unable to visit the toilet  
40 independently were excluded and not randomised.  
41  
42  
43

44  
45 **Intervention:** Early discharge from hospital after 3 days inpatient treatment. Home visits by  
46 generic community nurses. Primary outcome measure was change in health status measured  
47 by the Clinical COPD Questionnaire (CCQ). Treatment failures, readmissions, mortality and  
48 change in generic health-related quality of life (HRQL) were secondary outcome measures.  
49  
50  
51

52  
53  
54 **Results:** 139 patients were randomised. No difference between groups was found in change in  
55 CCQ score at day 7 (difference in mean change -0.29 (95% CI -0.61 to 0.03)) or at 3 months  
56  
57  
58  
59  
60

1  
2  
3 (difference in mean change -0.04 (95% CI -0.49 to 0.41)). No difference was found in  
4  
5 secondary outcomes. At day 7 there was a significant difference in change in generic HRQL,  
6  
7 favouring usual hospital care.  
8

9  
10 **Conclusion:** While patients' disease-specific health status after seven days treatment tended  
11  
12 to be somewhat better in the usual hospital care group, the difference was small and not  
13  
14 clinically relevant or statistically significant. After three months, the difference had  
15  
16 disappeared. A significant difference in generic health-related quality of life at the end of the  
17  
18 treatment had disappeared after 3 months and there was no difference in treatment failures,  
19  
20 readmissions or mortality. Early assisted discharge with community nursing is feasible and an  
21  
22 alternative to usual hospital care for selected patients with an acute COPD exacerbation  
23  
24  
25 COPD.  
26

27 **Trial registration:** NetherlandsTrialRegister NTR 1129  
28  
29  
30

### 31 **Article summary**

32 Article focus:

33  
34 - What is the effectiveness of early assisted discharge with community nursing for COPD  
35  
36 exacerbations in comparison to usual hospital care as measured by the Clinical COPD  
37  
38 Questionnaire.  
39  
40

41 Key Messages:

42  
43 - There is no short term or long term difference in change in health status as measured by the  
44  
45 Clinical COPD Questionnaire.  
46  
47  
48 - A significant difference in generic health-related quality of life at the end of the treatment  
49  
50 disappeared after 3 months.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 - Early assisted discharge with home visits by community nurses is a feasible and an  
4  
5 alternative to usual hospital care for selected patients with an acute exacerbation of their  
6  
7 COPD.  
8

9  
10 Strength and limitations:

11 - 139 patients were randomised where 165 was calculated to be the required sample size.

12  
13 However, because the difference between the groups was only 0.29 instead of 0.4 it is  
14  
15 unlikely that this difference would have increased to the clinically relevant difference of 0.4  
16  
17 with an additional 26 patients.  
18  
19

20 - This study is the first larger randomised controlled trial on early assisted discharge in the  
21  
22 Dutch health care system  
23  
24  
25  
26

## 27 **Introduction**

28  
29 Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with high prevalence  
30  
31 [1], mortality and morbidity [2,3]. Exacerbations of the disease have negative effects on  
32  
33 patient outcomes [4-6] and are the main cause for hospitalisation [7]. Hospitalisations are not  
34  
35 only the main cost driver in COPD, they also put pressure on scarce hospital beds, especially  
36  
37 during winters [8]. Several studies have shown that some patients with an exacerbation, who  
38  
39 would otherwise be admitted to the hospital, can be treated at home safely after examination  
40  
41 in the emergency department or a short hospital admission [9-16]. This is called hospital-at-  
42  
43 home. Hospital-at-home aims to avoid admission, or reduce length of stay (early assisted  
44  
45 discharge schemes). Previous studies found no differences in readmissions, mortality and  
46  
47 disease-specific quality of life between hospital-at-home and usual hospital care [9-11,15,16].  
48  
49  
50 Most published hospital-at-home studies originate from the United Kingdom and Spain,  
51  
52 where this service is mainly provided by hospital-based respiratory nurses who visit patients  
53  
54 at home. Davison et al. [17] and Nicholson et al. [18] suggested the use of non-specialised  
55  
56  
57  
58  
59  
60

1  
2  
3 'generic' community nursing teams for home supervision to increase the capacity of hospital-  
4  
5 at-home schemes.  
6  
7

8  
9  
10 The Netherlands has a nation-wide, good infrastructure for community nursing, which could  
11  
12 be used for hospital-at-home. Therefore we designed an early assisted discharge hospital-at-  
13  
14 home scheme for COPD exacerbations, mainly operated by generic community nurses who  
15  
16 performed the home visits [19]. Main objective of the GO AHEAD study (GO AHEAD is the  
17  
18 acronym for Assessment Of Going Home under Early Assisted Discharge) was to determine  
19  
20 the effectiveness and cost-effectiveness of early assisted discharge followed by community-  
21  
22 based nursing care at home. In addition, evaluation of patient satisfaction and preferences,  
23  
24 carer strain and preferences and an evaluation among professional care providers was  
25  
26 performed. The focus of this paper is on the effectiveness of early assisted discharge, with the  
27  
28 Clinical COPD Questionnaire (CCQ) as the primary outcome measure. In addition, treatment  
29  
30 failures, readmissions, mortality and generic quality of life were assessed as secondary  
31  
32 outcomes.  
33  
34  
35  
36  
37

### 38 **Methods**

39  
40 GO AHEAD was a randomised controlled trial comparing usual hospital care with early  
41  
42 assisted discharge for COPD exacerbations. Five hospitals and three home care organisations  
43  
44 participated. Treatment consisted of seven days in-hospital care as usual or three days in-  
45  
46 hospital treatment followed by four days care at home. Patients were followed until three  
47  
48 months after randomisation.  
49  
50  
51

52  
53 All patients admitted to one of the participating hospitals with a COPD exacerbation were  
54  
55 screened for potential eligibility on their first day of admission according to the inclusion and  
56  
57  
58  
59  
60

exclusion criteria (table 1). On day 3 of admission, clinical stability was assessed in patients who gave written informed consent (see randomisation criteria in table 1). For each hospital separately, participating patients were randomised on day 3 of admission, in a 1:1 ratio using a block-size of 6. Randomisation was performed by the study nurses. The randomisation sequence was computer-generated a priori by an independent researcher. Allocation sequence was placed in sealed envelopes. The study was approved by the Ethics Committee of the Catharina Hospital, the Netherlands, approval number M07-1755.

**Table 1** Inclusion and exclusion criteria (applied at admission) and randomisation criteria (applied at day 3 of admission)

Inclusion criteria (checked on day 1)	Exclusion criteria (checked on day 1)
Age $\geq$ 40 years	Major uncontrolled co morbidity
Competent to give informed consent	Mental disability
Diagnosed with COPD at least GOLD stage I and 10pack years of smoking	Living outside care region of the home care organisation
Hospitalisation for COPD exacerbation	Inability to understand the program
	Indication for admission to intensive care unit or for non invasive ventilation
	Active alcohol and/or drug abuse
	Insufficient availability of informal care at home
Randomisation criteria (checked on day 3)	
Completed Informed Consent on day three of admission	
Acceptable general health:	
- Decrease physical complaints	



- Non dependency of therapies that cannot be given at home
- Being able to visit toilet independently

Normal or moderately increased blood sugar levels, defined as  $\leq 15$  mmol/L or  $\geq 15$  mmol/L but patient is capable to regulate blood sugar levels independently

Respiratory complaints of dyspnoea, wheezing and rhonchi must have decreased in comparison with day of admission.

During the first three days of the admission all patients were treated in the hospital according to the study protocol [19]. Treatment consisted of systemic corticosteroids, nebulised bronchodilators and antibiotics and oxygen upon indication. Exacerbation symptoms were scored each day. Physiotherapists visited all patients for instruction of breathing and coughing techniques. On the fourth day of admission all randomised patients switched to oral medication and metered dosed inhalations. Patients randomised to early assisted discharge were discharged home on the fourth day of admission and further treated at home.

Community nurses visited or contacted the patient at least once daily on the day of discharge and the three consecutive days. They continued to score exacerbation symptoms and provided reassurance and counselling. Furthermore, medication compliance and inhalation techniques were addressed. Community nurses had the highest levels of generic nursing training in the Netherlands. No additional training was provided for the trial. The nurses could contact the hospital to discuss the patient's condition. If necessary, patients were readmitted to the hospital. For patients a 24-hour telephone access to the hospital respiratory ward was installed for emergencies.

Patients in the usual hospital care group received care as usual at the discretion of the hospital staff. General practitioners were informed about the patient's participation in the trial and the

1  
2  
3 discharge date. Clinical responsibility during home care remained with the respiratory  
4 physician. A detailed description of the research protocol and the early assisted discharge  
5 intervention has been published previously [19].  
6  
7  
8  
9

10  
11 Primary outcome was the change in CCQ scores between baseline (T0= day 3 of admission)  
12 and the end of the supervised treatment (T+4 days). The CCQ is a disease-specific  
13 questionnaire measuring health status [20]. It consists of 10 questions in three domains:  
14 symptoms, functional state and mental state, resulting in a overall score varying from 6 (worst  
15 score) to 0 (best score) [20]. The CCQ has proved to be responsive to change. The minimal  
16 clinical important difference is 0.4 [21]. To detect a difference of 0.4 in CCQ change scores  
17 between the two groups, in favour of the early discharge group, with a power of 0.80 and  
18 alpha of 0.05, the required sample size was 165 [19]. Secondary outcomes were: 1) change in  
19 CCQ scores between baseline and three months after randomisation (T+90 days); 2) number  
20 of treatment failures (i.e. either death or clinical deterioration leading to prolonged hospital  
21 stay beyond the standardised seven days (usual hospital care) or death or readmission during  
22 the four days treatment at home (early discharge)); 3) mortality and 4) readmissions during  
23 the three month follow-up; and 5) generic health-related quality of life measured by the  
24 EuroQol-5D (EQ-5D)[22] at baseline, T+4 days and T+90 days. Utilities were calculated  
25 using the Dutch value set [22]. Higher scores represent better generic quality of life.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

#### 47 **Statistical analysis**

48  
49 Change in CCQ scores and EQ-5D scores was analysed using a repeated measures model with  
50 an unstructured covariance matrix. Backward selection of covariates was applied. In addition  
51 to time (i.e. measurement at T+4 days, end of treatment, and T+90 days, end of follow-up),  
52 the interaction of time and treatment, the following variables were tested: baseline CCQ or  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 EQ-5D score, treatment centre, age, gender, comorbidity, smoking status, living situation,  
4  
5 availability informal caregiver, presence of home care prior to admission, course of oral  
6  
7 corticosteroids and/or antibiotics prior to admission. Variables were retained in the model if  
8  
9 their exclusion led to a 10% change in the estimated treatment effect [23]. For the analysis of  
10  
11 CCQ scores, only baseline score was included in the final model. For the analysis of EQ-5D  
12  
13 scores, baseline score, comorbidity and gender were included. Results are presented as mean  
14  
15 differences in change and 95% confidence intervals (95% CI). Numbers of patients with  
16  
17 treatment failures, readmissions and mortality were analysed using multiple logistic  
18  
19 regression analysis. Numbers of readmissions per patient in each group were analysed in a  
20  
21 Poisson regression. Time to readmission was analysed with a Cox proportional hazards  
22  
23 model. Results are presented as odds ratios (OR) or hazard ratios (HR) with 95% CI. Again,  
24  
25 backward selection was used to select covariates. Only baseline CCQ score was retained in  
26  
27 the models. The significance level for a difference between treatment groups was set at  
28  
29  $p \leq 0.05$ .  
30  
31  
32  
33  
34  
35

## 36 **Results**

37  
38 In total, 1371 patients were screened for eligibility between November 2007 and March 2011,  
39  
40 of whom 508 met the criteria for eligibility on day 1. Figure 1 shows an overview of the  
41  
42 patient flow during the trial from hospital admission to the end of the follow-up. Three  
43  
44 patients in the early assisted discharge group and 7 in the usual hospital care group were not  
45  
46 satisfied with the allocated place of treatment and withdrew consent immediately after  
47  
48 randomisation. The total dropout over the study period was 16%, 25% in the usual hospital  
49  
50 care group and 10% in the early assisted discharge group. Baseline CCQ scores of patients  
51  
52 dropping out were not different from those who completed the study, but they did have more  
53  
54 comorbidities. Table 2 shows the baseline characteristics of randomised patients by treatment  
55  
56  
57  
58  
59  
60

group. These were comparable across the groups. At end of the follow-up period lung function testing was performed by which classification of disease severity according to the GOLD criteria [2] could be made (supplementary data file 1).

**Figure 1** Patient flow through study.

**Table 2** Baseline characteristics and treatment at admission. Values represent mean (SD), unless stated otherwise.

Characteristic	Usual hospital care (N=69)	Early assisted discharge (N=70)
Age (years)	67.8 (11.3)	68.3 (10.3)
Men (%)	38 (55.1)	48 (68.6)
<i>Smoking history:</i>		
Current smokers (%)	27 (39.1)	23 (32.9)
Pack years, median	37	44
inter quartile range	36.9	26.7
Body Mass Index (kg/m <sup>2</sup> )	25.6 (4.3)	25.0 (5.1)
Charlson comorbidity score <sup>24,†</sup>	1.68 (1.1)	1.74 (1.1)
Comorbidity score of 1 (%)	42 (60.0)	38 (54.0)
Comorbidity score > 1 (%)	27 (39.0)	32 (46.0)
<i>Living situation:</i>		
Living alone (%)	21 (30.4)	22 (31.4)
Receiving care at home before admission (%)	16 (23.2)	17 (24.3)
<i>Treatment at admission:</i>		
Long term oxygen treatment (%)	4 (5.8)	5 (7.1)

Oral steroids (%)	5 (7.2)	10 (14.3)
Course of oral steroids prior to admission (%)	34 (50.0)	35 (50.7)
Course antibiotics prior to admission (%)	31 (45.6)	32 (46.4)
Inhaled $\beta$ 2-agonist (LABA) (%)	9 (13.0)	7 (10.0)
Inhaled corticosteroid (%)	3 (12.0)	3 (15.0)
Inhaled corticosteroid/LABA combination (%)	44 (63.7)	50 (71.4)
Inhaled anticholinergic (%)		
Tiotropium	31 (44.9)	36 (51.4)
Ipratropium	12 (17.4)	13 (18.6)
Followed rehabilitation program in year prior to admission (%)	10 (14.9)	12 (17.4)
Heart Rate (beats/minute)	91.0 (14.2)	95.6 (18.4)
Arterial blood gas <sup>#</sup> :	N=37	N=42
pH	7.44 (0.05)	7.43 (0.04)
pO <sub>2</sub> (mmHg)	70.7 (13.2)	67.3 (8.1)
pCO <sub>2</sub> (mmHg)	37.2 (6.2)	39.1 (5.3)
Saturation	94 (2.5)	94 (3.6)

† Charlson Comorbidity Index, 1= only COPD, higher score means more comorbidities; # only data of blood gas measurements in patients without oxygen supplement; LABA: long acting beta2 agonist

Supplementary file 2 shows the unadjusted CCQ scores at the different measuring points. At T0 CCQ scores were 2.22 (0.97) for the usual hospital care group and 2.63 (1.06) for the early discharge group. Figure 2 shows the change in CCQ scores from T0, adjusted for baseline score. CCQ scores improved between T0 and T+4 days for the usual hospital care group, and were almost stable for the early assisted discharge group, but there was no significant

1  
2  
3 difference between the groups at T+4 days (difference in mean change from T0 -0.29, 95% CI  
4  
5 -0.61 to 0.03,  $p=0.078$ ). At T+90 days, CCQ scores of both groups scores were  
6  
7 slightly higher in comparison to T0. There was no difference between the groups at three  
8  
9 months (difference in mean change from T0 -0.04, 95% CI -0.48 to 0.41,  $p=0.858$ ).

10  
11  
12  
13  
14 **Figure 2 CCQ total score, differences in mean change from baseline**

15  
16  
17 Treatment failed in five patients. One patient in the early discharge group needed readmission  
18  
19 to the hospital before the end of the home treatment and 4 patients in the usual hospital care  
20  
21 group required hospital admission beyond the 7 days that were stated in the protocol. This  
22  
23 difference was not significant (OR early discharge group 0.27, 95% CI 0.026 – 2.70,  
24  
25  $p=0.263$ ). Table 3 shows the number of readmissions during follow-up. Seventeen patients in  
26  
27 each group had 1 or more readmission to the hospital of which 14 first readmissions were due  
28  
29 to an exacerbation or other pulmonary indication (OR early discharge group 0.80, 95% CI  
30  
31 0.36 – 1.79,  $p=0.592$ ). There was no difference in the number of readmissions per patient  
32  
33 between the groups, or in the total number of readmissions in each group. There was no  
34  
35 difference in time to first readmission between the two groups (HR early discharge group  
36  
37 0.77, 95% CI 0.39 to 1.53,  $p=0.461$ ).

38  
39  
40  
41  
42  
43  
44 **Table 3** Readmissions during follow-up. Values are numbers of patients (%).

45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Usual hospital care	Early assisted discharge
Patients with readmission	17 (25)	17 (24)
Patients with 1, 2 or $\geq 3$ readmissions		
1 readmission	11	12

2 readmissions	4	3
3 or more readmissions	2	2

No patient died during the hospital or home treatment, but 1 patient from each group died during follow-up. Cause of death was unknown in one case (patient died during sleep at home) and an acute abdomen in the other. Both were not related to the trial.

EQ-5D utility scores (SD) at T0 were 0.713 (0.22) for the usual hospital care group and 0.664 (0.26) for the early assisted discharge group. Table 4 shows the mean changes and mean difference in change from baseline of EQ-5D utility. In the usual hospital care group, mean utility scores improved from T0 to T+4 days and decreased to baseline at T+90 days. In the early assisted discharge group mean utility scores remained close to baseline. The mean change in utility scores on T+4 days was significant greater in the usual hospital care group. At T+90 days this difference between treatment groups had disappeared.

**Table 4** Mean changes and mean differences in change for EQ-5D.

		Mean change from baseline (SE)		Adjusted mean (95% CI) difference in change from baseline*	p value
Utility		Usual hospital care	Early assisted discharge	Usual care - early discharge	
	T+ 4 days†	0.051 (0.0261)	-0.005 (0.029)	0.0746 (0.010 to 0.139)	0.024
	T+ 90 days‡	-0.036 (0.0447)	0.008 (0.039)	-0.022 (-0.116 to 0.072)	0.639

\*Results from repeated measures analysis, adjusted for baseline value † hospital care N=57, early discharge N=61; ‡ hospital care N=47, early discharge N=54  
SE: Standard Error; 95% CI: 95% Confidence Interval

## Discussion

This is the first randomised controlled trial that investigated the effectiveness of early assisted discharge for COPD exacerbations with supervision at home by community nurses. In addition, this is the first evaluation of early discharge for this disease in the Dutch health care system. While patients' disease-specific health status as expressed in the mean CCQ score after seven days treatment tended to be somewhat better in the usual hospital care group, the difference was small, not clinically relevant and not statistically significant. After three months, the difference had disappeared. The same pattern was found in generic health-related quality of life measured with the EQ-5D, although this difference was statistically significant at the end of the supervised treatment. The difference had disappeared at the end of the 3-month follow up period. There was no difference in treatment failures, readmissions or mortality.

These study results confirm previously published positive results by Davison et al. [17] and Nicholson et al. [18], but these two studies were either not randomised [17] or included a small number of patients [18]. We found no significant difference in CCQ scores, which corresponds with the findings of Davies et al. [9] and Hernandez et al. [16], who found no differences in disease-specific quality of life measured with the St George's Respiratory Questionnaire. Furthermore, our results are in line with those of earlier studies involving specialised hospital-based nurses [9-12,15,16,24,25]. The readmission rate in our study was 25%, which is comparable to the 30% in previously published studies [9-11]. Characteristics like age, smoking history and living situation of patients in our study were similar to those in studies from the United Kingdom [9-12] and to that of a survey on hospital-at-home services in British hospitals by Quantrill et al. [26].



1  
2  
3 Earlier studies did not measure the impact of hospital-at-home on generic health-related  
4  
5 quality of life. We found a significant difference between the two groups, in favour of usual  
6  
7 hospital care, at the end of the hospital and home treatment. This difference had disappeared  
8  
9 after three months. The utility scores are in line with O'Reilly et al. [27], but they found  
10  
11 much worse scores at admission than in our study, probably because we did not include  
12  
13 patients with more severe exacerbations. Utility and CCQ scores in both groups follow the  
14  
15 same pattern. The greater improvement in CCQ and EQ-5D scores of the usual hospital care  
16  
17 group at the end of the hospital treatment in comparison to the early discharge group may  
18  
19 reflect a true difference in recovery, in which case usual hospital care is the preferred  
20  
21 treatment. However, an alternative explanation could be that patients who were discharged  
22  
23 early were confronted with their symptoms and limitations earlier and more intensely when  
24  
25 they tried to pick up normal life at home. Furthermore, some patients have difficulties  
26  
27 viewing hospital care followed by early discharge as one treatment period [28]. Expecting to  
28  
29 be in a certain state at discharge, and experiencing this is not the case, might be expressed in  
30  
31 worse scores on the CCQ and the EQ-5D.  
32  
33  
34  
35  
36  
37

38 In our trial multiple hospitals participated with different socioeconomic and geographic  
39  
40 characteristics, which makes it likely that our sample is representative of eligible patients. The  
41  
42 percentage of admissions initially considered to be eligible for early discharge at admission  
43  
44 was similar to that of previous studies ( $\pm 37\%$ ). Early discharge is possible when the  
45  
46 exacerbation is the main problem and comorbidities are (relatively) stable. The percentage of  
47  
48 patients living alone suggests that this is not an absolute reason for exclusion, provided that  
49  
50 patients have a sufficiently functioning social support system. Still, 25% of screened patients  
51  
52 were considered ineligible, because of living in a nursing home, overburden of informal  
53  
54 caregiver(s) or living alone with insufficient social support. This suggests that social  
55  
56  
57  
58  
59  
60

1  
2  
3 environment is an important factor when deciding for admission and (early) discharge.

4  
5 Finally, 37% of screened patients was ineligible because of comorbidities.  
6  
7

8  
9  
10 Considering the very low number of treatment failures in the early discharge group it might be  
11 possible to relax the inclusion criteria and randomisation criteria. In our trial, criteria were  
12 applied very strictly for safety reasons, but more patients with comorbidities might be eligible  
13 in daily practice. Furthermore, the strict review and exclusion of patients at day 1 of  
14 admission (e.g. those treated with NIV), precluded patients from early discharge even if they  
15 had become eligible at day 3 of admission. Therefore, review of eligibility for early discharge  
16 should be performed after a few days of hospital treatment. Thirty percent of patients who  
17 consented to participate were not randomised because they showed insufficient recovery  
18 and/or were depending on oxygen supply. Unlike in the British hospital-at-home schemes,  
19 patients were not sent home with nebulisers or oxygen cylinders, unless these were already  
20 part of their treatment. Extension of the treatment possibilities at home may enable early  
21 discharge of patient with more severe disease. However, it would also require more expertise  
22 of the nursing staff supervising patients at home, which might currently not be present in  
23 community-based home care organisations. Future research should focus on determining  
24 which treatments can be safely provided at home, which treatments require the supervision of  
25 generic or specialised nurses and which criteria should be applied for selecting eligible  
26 patients. In addition, a direct comparison between early discharge with generic and early  
27 discharge with specialised nursing care would provide more information on which scheme is  
28 most safe and effective.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53  
54 Our study has some limitations. Firstly, in total 139 patients were randomised, where a  
55 number of 165 was calculated to be needed to detect a difference of 0.4 in CCQ change scores  
56  
57  
58  
59  
60

1  
2  
3 between the two groups. A post-hoc power analysis with these 139 patients and the actual  
4  
5 variances in CCQ scores showed that the power to detect a difference in change from baseline  
6  
7 of 0.4 between the groups was 73% instead of 80%, which was aimed for. We believe that  
8  
9 this slight reduction in power does not have a substantial influence on our final results,  
10  
11 because the difference between the groups was only 0.29. It is highly unlikely that this  
12  
13 difference would have increased to the clinically relevant difference of 0.4 with an additional  
14  
15 26 patients. In previous randomised studies of early discharge in patients diagnosed with  
16  
17 COPD numbers varied between 25 and 222, and only 15 to 35% of admitted patients was  
18  
19 randomised [9-12,16,29]. Secondly, our study was not an equivalence trial, which would  
20  
21 determine best whether hospital care and early discharge care are equally effective. However,  
22  
23 in order to demonstrate equal effectiveness with CCQ score, over 500 patients would have  
24  
25 been needed, which is beyond what is attainable in this population. Thirdly, 16% of patients  
26  
27 dropped out after randomisation. However, comparison of patients who dropped out with  
28  
29 patients who completed the study only revealed more comorbidities for those who dropped  
30  
31 out. CCQ scores were not different. Finally, due to the nature of the intervention, patients and  
32  
33 health care staff could not be blinded to the allocated group.  
34  
35  
36  
37  
38  
39

40  
41 In conclusion, we found no significant short-term or long-term differences in outcomes  
42  
43 between early discharge and usual hospital care, except for generic health-related quality of  
44  
45 life at the end of treatment (T+4 days). Early assisted discharge with home visits by  
46  
47 community nurses can reduce length of hospital stay for a selected group of patients admitted  
48  
49 with a COPD exacerbation and is an alternative to usual hospital care. The decision to  
50  
51 implement early assisted discharge with community nursing does not only depend on the  
52  
53 results of the effectiveness analysis. Costs and cost-effectiveness evaluations are of high  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 importance as well. An economic evaluation is currently being performed and results will be  
4  
5 published separately.  
6  
7  
8

### 9 10 **Funding**

11 The study was funded by the Netherlands Organisation for Health Research and Development  
12 (ZonMw), grant application number 945-50-7730. The funder had no role in the design of the  
13 study; the collection analysis and interpretation of the data; or the writing of the article and  
14 the decision to submit the article for publication. All researchers were independent from the  
15 funder.  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Copyright/licence for publication**

26 The Corresponding Author has the right to grant on behalf of all authors and does grant on  
27 behalf of all authors, a **worldwide licence** to the Publishers and its licensees in perpetuity, in  
28 all forms, formats and media (whether known now or created in the future), to i) publish,  
29 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into  
30 other languages, create adaptations, reprints, include within collections and create summaries,  
31 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on  
32 the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of  
33 electronic links from the Contribution to third party material where-ever it may be located;  
34 and, vi) licence any third party to do any or all of the above.”  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **Competing interests**

51 “All authors have completed the Unified Competing Interest form at  
52 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and  
53 declare that (1) LG, MR, OvS have had support from ZonMw for the submitted work; (2) CU,  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 FS, MvV, MB, LvE have no relationships with companies that might have an interest in the  
4 submitted work in the previous 3 years; LG and MR have relationships (received grants to  
5 perform cost- and cost-effectiveness studies) from multiple pharmaceutical companies, OvS  
6 has relationships (consultancy) with Pfizer, Boehringer Ingelheim and Astra Zeneca that  
7 might have an interest in the submitted work in the previous 3 years; (3) their spouses,  
8 partners, or children have [specified] financial relationships that may be relevant to the  
9 submitted work; and (4) CU, LG, FS, MR, MvV, MB, LvE and OvS have no non-financial  
10 interests that may be relevant to the submitted work.”  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 **Contributors**

25  
26 CU was involved in patient recruitment, database management, administration of  
27 questionnaires, data analysis, data interpretation and wrote the manuscript. LG was involved  
28 in data analysis and data interpretation and preparation of the manuscript. FS was local  
29 coordinating physician and involved in data interpretation and preparation of the manuscript.  
30 MR designed the study and involved in data interpretation and preparation of the manuscript.  
31 MvV was local coordinating physician in the Atrium Medical Centre and involved in the  
32 preparation of the manuscript. MB and LvE were coordinators of the home care organisations  
33 and involved in the preparation of the manuscript. OvS designed the study and was involved  
34 in data interpretation and writing the manuscript. OvS is guarantor for the study. All  
35 researchers had access to all data.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 **Acknowledgements**

51  
52 The authors thank all care professionals from the participating hospitals and home care  
53 organisations that made the trial and early assisted discharge possible: W. van Litsenburg  
54 (Catharina-hospital), A. Janssen (Catharina-hospital), W. Seezink (Atrium Medical Centre),  
55  
56  
57  
58  
59  
60

1  
2  
3 B. van de Pas (Máxima Medical Centre), A. van der Pouw (Rijnstate Hospital) and P. de Laat  
4  
5 (TweeSteden Hospital) who performed patient recruitment; R. Eijsermans who coordinated  
6  
7 the home care visits in the Tilburg region; D. DeMunck (Máxima Medical Centre), J. Retera  
8  
9 (TweeSteden Hospital) and P. de Bruijn (Rijnstate Hospital) who were responsible  
10  
11 pulmonologists in the participating hospitals. We thank K. van der Meer, research assistant,  
12  
13 for her assistance in the data input.  
14  
15

### 16 17 18 **Data sharing**

19  
20 No additional data available  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References


1. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007;370:741-750.
2. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;176:532-555.
3. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J* 2006;27:397-412.
4. Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;157:1418-1422.
5. Donaldson GC, Seemungal TA, Bhowmik A et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002;57:847-852.
6. Esteban C, Quintana JM, Moraza J et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. *Respir Med* 2009;103:1201-1208.
7. Toy EL, Gallagher KF, Stanley EL et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. *COPD* 2010;7:214-228.
8. Jordan RE, Hawker JI, Ayres JG et al. Effect of social factors on winter hospital admission for respiratory disease: a case-control study of older people in the UK. *Br J Gen Pract* 2008;58:400-402.

- 1  
2  
3 9. Davies L, Wilkinson M, Bonner S et al. "Hospital at home" versus hospital care in  
4 patients with exacerbations of chronic obstructive pulmonary disease: prospective  
5 randomised controlled trial. *BMJ* 2000;321:1265-1268.  
6  
7
- 8  
9  
10 10. Cotton MM, Bucknall CE, Dagg KD et al. Early discharge for patients with  
11 exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.  
12 *Thorax* 2000;55:902-906.  
13  
14
- 15  
16 11. Skwarska E, Cohen G, Skwarski KM et al. Randomized controlled trial of supported  
17 discharge in patients with exacerbations of chronic obstructive pulmonary disease.  
18 *Thorax* 2000;55:907-912.  
19  
20
- 21  
22 12. Ojoo JC, Moon T, McGlone S et al. Patients' and carers' preferences in two models of  
23 care for acute exacerbations of COPD: results of a randomised controlled trial. *Thorax*  
24 2002;57:167-169.  
25  
26
- 27  
28 13. British Thoracic Society. Intermediate care--Hospital-at-Home in chronic obstructive  
29 pulmonary disease: British Thoracic Society guideline. *Thorax* 2007;62:200-210.  
30  
31
- 32  
33 14. Diaz LS, Gonzalez LF, Gomez Mendieta MA et al. [Evaluation of a home  
34 hospitalization program in patients with exacerbations of chronic obstructive  
35 pulmonary disease]. *Arch Bronconeumol* 2005;41:5-10.  
36  
37
- 38  
39 15. Gravil JH, Al-Rawas OA, Cotton MM et al. Home treatment of exacerbations of  
40 chronic obstructive pulmonary disease by an acute respiratory assessment service.  
41 *Lancet* 1998;351:1853-1855.  
42  
43
- 44  
45 16. Hernandez C, Casas A, Escarrabill J et al. Home hospitalisation of exacerbated chronic  
46 obstructive pulmonary disease patients. *Eur Respir J* 2003;21:58-67.  
47  
48
- 49  
50 17. Davison AG, Monaghan M, Brown D et al. Hospital at home for chronic obstructive  
51 pulmonary disease: an integrated hospital and community based generic intermediate  
52 care service for prevention and early discharge. *Chron Respir Dis* 2006;3:181-185.  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 18. Nicholson C, Bowler S, Jackson C et al. Cost comparison of hospital- and home-based  
4 treatment models for acute chronic obstructive pulmonary disease. *Aust Health Rev*  
5 2001;24:181-187.  
6  
7
- 8  
9  
10 19. Utens CM, Goossens LM, Smeenk FW et al. Effectiveness and cost-effectiveness of  
11 early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the  
12 design of a randomised controlled trial. *BMC Public Health* 2010;10:618  
13  
14
- 15  
16 20. van der Molen T, Willemse BW, Schokker S et al. Development, validity and  
17 responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes*  
18 2003;1:13  
19  
20
- 21  
22 21. Kocks JW, Tuinenga MG, Uil SM et al. Health status measurement in COPD: the  
23 minimal clinically important difference of the clinical COPD questionnaire. *Respir*  
24 *Res* 2006;7:62  
25  
26
- 27  
28  
29 22. Lamers LM, McDonnell J, Stalmeier PF et al. The Dutch tariff: results and arguments  
30 for an effective design for national EQ-5D valuation studies. *Health Econ*  
31 2006;15:1121-1132.  
32  
33
- 34  
35 23. Rothman KJ, Greenland S, Lash TL. *Modern Epidemiology* (3rd edition).  
36 Philadelphia: Lippincott Williams & Wilkins 2008.  
37  
38
- 39  
40 24. Ansari K, Shamssain M, Farrow M et al. Hospital-at-home care for exacerbations of  
41 chronic obstructive pulmonary disease: an observational cohort study of patients  
42 managed in hospital or by nurse practitioners in the community. *Chron Respir Dis*  
43 2009;6:69-74.  
44  
45
- 46  
47  
48 25. Sala E, Alegre L, Carrera M et al. Supported discharge shortens hospital stay in  
49 patients hospitalized because of an exacerbation of COPD. *Eur Respir J* 2001;17:1138-  
50 1142.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


- 1  
2  
3 26. Quantrill SJ, Lowe D, Hosker HS et al. Survey of early discharge schemes from the  
4  
5 2003 UK National COPD Audit. *Respir Med* 2007;101:1026-1031.  
6  
7 27. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with  
8  
9 COPD exacerbation managed in hospital. *Int J Clin Pract* 2007;61:1112-1120.  
10  
11 28. Clarke A, Sohanpal R, Wilson G et al. Patients' perceptions of early supported  
12  
13 discharge for chronic obstructive pulmonary disease: a qualitative study. *Qual Saf*  
14  
15 *Health Care* 2010;19:95-98.  
16  
17 29. Aimonino RN, Tibaldi V, Leff B et al. Substitutive "hospital at home" versus inpatient  
18  
19 care for elderly patients with exacerbations of chronic obstructive pulmonary disease:  
20  
21 a prospective randomized, controlled trial. *J Am Geriatr Soc* 2008;56:493-500.  
22  
23 30. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic  
24  
25 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*  
26  
27 1987;40:373-383  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



\*Not asked to participate because of logistical reasons (e.g. no study staff available or patient not admitted to respiratory ward)  
226x182mm (300 x 300 DPI)

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Error bars represent standard errors. P values are based on repeated measures analysis, adjusted for baseline value.

\*Number of patients at T+4 days that completed questionnaire that produced valid total score; \*\*number of patients at T+90 days that completed questionnaire that produced valid total score.

128x86mm (300 x 300 DPI)

**Supplemental file 1**

Lung function testing at end of 3 month follow-up. Values represent mean (SD)

	Usual hospital care	Early assisted discharge
Postbronchodilator FEV <sub>1</sub> (litres)	1.25 (0.07)	1.21 (0.07)
% of predicted postbronchodilator FEV <sub>1</sub>	50.29 (2.71)	45.20 (2.13)
% GOLD stage I	10.3	2.9
% GOLD stage II	32.4	32.9
% GOLD stage III	41.2	44.3
% GOLD stage IV	16.2	20.0

**Supplementary file 2**

Unadjusted CCQ total scores (SD) at each time of measurement by treatment group.

Time of measurement	Usual hospital care	Early assisted discharge
T- 2 days	3.21 (1.07)	3.49 (1.07)
T0	2.22 (0.97)	2.63 (1.06)
T+ 4 days	2.00 (1.09)	2.55 (1.21)
T+ 90 days	2.41 (1.14)	2.70 (1.32)

CCQ total score range is 0-6;

0 represents best possible score and 6 represents worst possible score



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	5-6
	2b	Specific objectives or hypotheses	5-6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6-7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	n/a
Participants	4a	Eligibility criteria for participants	6-7 & table 1
	4b	Settings and locations where the data were collected	6-7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	8-9 & reference 19
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9
	6b	Any changes to trial outcomes after the trial commenced, with reasons	n/a
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n/a
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7

1			
2	Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
3			18
4		11b	If relevant, description of the similarity of interventions
5			8-9
6	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes
7		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses
8			n/a
9	<b>Results</b>		
10	Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome
11			10 & fig 1
12		13b	For each group, losses and exclusions after randomisation, together with reasons
13			10 & fig 1
14	Recruitment	14a	Dates defining the periods of recruitment and follow-up
15		14b	Why the trial ended or was stopped
16			n/a
17	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group
18			table 2
19	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
20			All tables and figures with results
21			
22	Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)
23			13-14
24			Tables & figures
25		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended
26			n/a
27	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
28			n/a
29			
30	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
31			n/a
32	<b>Discussion</b>		
33	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
34			18
35	Generalisability	21	Generalisability (external validity, applicability) of the trial findings
36			15 to 18
37	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
38			15 to 18
39	<b>Other information</b>		
40	Registration	23	Registration number and name of trial registry
41			abstract
42	Protocol	24	Where the full trial protocol can be accessed, if available
43			Reference 19
44	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders
45			19



1  
2 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also  
3 recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.  
4 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only



**EARLY ASSISTED DISCHARGE WITH COMMUNITY NURSING  
FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
EXACERBATIONS: RESULTS OF A RANDOMISED  
CONTROLLED TRIAL**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001684.R1
Article Type:	Research
Date Submitted by the Author:	14-Aug-2012
Complete List of Authors:	Utens, Cecile; Department of Respiratory Medicine, Catharina Hospital, ; CAPHRI School for Public Health and Primary Care, Maastricht University, Goossens, Lucas; Institute for Medical Technology Assessment, Erasmus University, Smeenk, Frank; Department of Respiratory Medicine, Catharina Hospital, Rutten-van Mólken, Maureen; Institute for Medical Technology Assessment, Erasmus University, van Vliet, Monique; Department of Respiratory Medicine, Atrium Medical Centre, Braken, Maria; Department of Staff nurses Nursing and Care, ZuidZorg, van Eijsden, Loes; Department of Health Care Policy, Meander Group Zuid-Limburg, van Schayck, Onno; CAPHRI School for Public Health and Primary Care, Maastricht University,
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	Chronic airways disease < THORACIC MEDICINE, PRIMARY CARE, Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

**Title:**

Early assisted discharge with generic community nursing for Chronic Obstructive Pulmonary  
Disease exacerbations: results of a randomised controlled trial

Cecile MA Utens<sup>1,2</sup>, Lucas MA Goossens<sup>3</sup>, Frank WJM Smeenk<sup>1</sup>, Maureen PMH Rutten-van  
Mölken<sup>3</sup>, Monique van Vliet<sup>4</sup>, Maria W Braken<sup>5</sup>, Loes MGA van Eijnsden<sup>6</sup>, Onno CP van  
Schayck<sup>2</sup>

**Affiliations:**

<sup>1</sup>Department of Respiratory Medicine, Catharina-hospital Eindhoven, Eindhoven, the  
Netherlands, P.O. Box 1350 ZA Eindhoven, the Netherlands

<sup>2</sup>Department of General Practice, CAPHRI School for Public Health and Primary Care,  
Maastricht University, Maastricht, the Netherlands, P.O. box 616 6200 MD Maastricht, the  
Netherlands

Cecile MA Utens

PhD candidate

<sup>3</sup>Institute for Medical Health Technology Assessment, Erasmus University, Rotterdam, the  
Netherlands, P.O. box 1738 3000 DR Rotterdam, the Netherlands

Lucas MA Goossens

Researcher/ PhD candidate

<sup>1</sup>Department of Respiratory Medicine, Catharina-hospital Eindhoven, Eindhoven, the  
Netherlands, P.O. Box 1350 ZA Eindhoven, the Netherlands

Frank WJM Smeenk

1  
2  
3 Pulmonologist  
4  
5  
6

7 <sup>3</sup>Institute for Medical Health Technology Assessment, Erasmus University, Rotterdam, the  
8 Netherlands, P.O. box 1738 3000 DR Rotterdam, the Netherlands  
9

10  
11 Maureen PMH Rutten-van Mölken

12  
13  
14 Professor  
15  
16

17  
18 <sup>4</sup>Department of Respiratory Medicine, Atrium Medical Centre, Heerlen, the Netherlands, P.O.  
19 box 4446 6401 CZ Heerlen, the Netherlands  
20  
21

22  
23 Monique van Vliet

24  
25 Pulmonologist  
26  
27

28  
29 <sup>5</sup>Department of Staff nurses Nursing and Care, ZuidZorg, Veldhoven, the Netherlands, P.O.  
30 box 2160 5500 BD Veldhoven, the Netherlands  
31  
32

33  
34 Maria Braken

35  
36 Staff nurse  
37  
38

39  
40 <sup>6</sup>Department of Health Care Policy, Meander Group Zuid-Limburg, Heerlen, the Netherlands  
41 P.O. box 2690 6401 DD Heerlen, the Netherlands  
42  
43

44  
45 Loes van Eijnsden

46  
47 Policy officer  
48  
49

50  
51 <sup>2</sup>Department of General Practice, CAPHRI School for Public Health and Primary Care,  
52 Maastricht University, Maastricht, the Netherlands, P.O. box 616 6200 MD Maastricht, the  
53 Netherlands  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Onno CP van Schayck

4  
5 Professor

6  
7  
8  
9 **Corresponding author:**

10  
11 Cecile Utens

12  
13 Email: cecileutens@gmail.com

14  
15  
16  
17  
18 **Keywords:** Hospital at home; Early assisted discharge from hospital; Chronic Obstructive  
19  
20 Pulmonary Disease; Community nursing, Randomised controlled trial  
21  
22

23  
24  
25 **Abstract**

26  
27 **Objectives:** To determine effectiveness of early assisted discharge for COPD exacerbations,  
28  
29 with home care provided by generic community nurses, compared to usual hospital care.

30  
31 Design: Prospective, randomised controlled, multi-centre trial with 3 months follow-up.

32  
33 **Setting:** Five hospitals and 3 home care organisations in the Netherlands.

34  
35  
36 **Participants:** Patients admitted to the hospital with an exacerbation of Chronic Obstructive  
37  
38 Pulmonary Disease. Patients with no or limited improvement of respiratory symptoms and  
39  
40 patients with severe unstable comorbidities, social problems or those unable to visit the toilet  
41  
42 independently were excluded.  
43  
44

45  
46 **Intervention:** Early discharge from hospital after 3 days inpatient treatment. Home visits by  
47  
48 generic community nurses. Primary outcome measure was change in health status measured  
49  
50 by the Clinical COPD Questionnaire (CCQ). Treatment failures, readmissions, mortality and  
51  
52 change in generic health-related quality of life (HRQL) were secondary outcome measures.  
53

54  
55 **Results:** 139 patients were randomised. No difference between groups was found in change in  
56  
57 CCQ score at day 7 (difference in mean change 0.29 (95% CI -0.03 to 0.61)) or at 3 months  
58  
59  
60

1  
2  
3 (difference in mean change 0.04 (95% CI -0.40 to 0.49)). No difference was found in  
4  
5 secondary outcomes. At day 7 there was a significant difference in change in generic HRQL,  
6  
7 favouring usual hospital care.  
8

9  
10 **Conclusion:** While patients' disease-specific health status after seven days treatment tended  
11  
12 to be somewhat better in the usual hospital care group, the difference was small and not  
13  
14 clinically relevant or statistically significant. After three months, the difference had  
15  
16 disappeared. A significant difference in generic health-related quality of life at the end of the  
17  
18 treatment had disappeared after 3 months and there was no difference in treatment failures,  
19  
20 readmissions or mortality. Early assisted discharge with community nursing is feasible and an  
21  
22 alternative to usual hospital care for selected patients with an acute COPD exacerbation.  
23  
24

25 **Trial registration:** Netherlands Trial Register NTR 1129  
26  
27

## 28 29 **Article summary**

30  
31 Article focus:

32  
33 - What is the effectiveness of early assisted discharge with community nursing for COPD  
34  
35 exacerbations in comparison to usual hospital care as measured by the Clinical COPD  
36  
37 Questionnaire.  
38  
39

40  
41 Key Messages:

42  
43 - There is no short term or long term difference in change in health status as measured by the  
44  
45 Clinical COPD Questionnaire.

46  
47 - A significant difference in generic health-related quality of life at the end of the treatment  
48  
49 disappeared after 3 months.

50  
51 - Early assisted discharge with home visits by community nurses is a feasible and an  
52  
53 alternative to usual hospital care for selected patients with an acute exacerbation of their  
54  
55 COPD.  
56  
57  
58  
59  
60

1  
2  
3 Strength and limitations:

4  
5 - 139 patients were randomised where 165 was calculated to be the required sample size.

6  
7 However, because the difference between the groups was only 0.29 instead of 0.4 it is  
8  
9 unlikely that this difference would have increased to the clinically relevant difference of 0.4  
10  
11 with an additional 26 patients.

12  
13 - This study is the first larger randomised controlled trial on early assisted discharge in the  
14  
15 Dutch health care system  
16  
17

## 18 19 20 21 **Introduction**

22  
23 Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with high prevalence  
24  
25 [1], mortality and morbidity [2,3]. Exacerbations of the disease have negative effects on  
26  
27 patient outcomes [4-6] and are the main cause for hospitalisation [7]. Hospitalisations are not  
28  
29 only the main cost driver in COPD, they also put pressure on scarce hospital beds, especially  
30  
31 during winters [8]. Several studies have shown that some patients with an exacerbation, who  
32  
33 would otherwise be admitted to the hospital, can be treated at home safely after examination  
34  
35 in the emergency department or a short hospital admission [9-16]. This is called hospital-at-  
36  
37 home. Hospital-at-home aims to avoid admission, or reduce length of stay (early assisted  
38  
39 discharge schemes). Previous studies found no differences in readmissions, mortality and  
40  
41 disease-specific quality of life between hospital-at-home and usual hospital care [9-11,15,16].  
42  
43 Most published hospital-at-home studies originate from the United Kingdom and Spain,  
44  
45 where this service is mainly provided by hospital-based respiratory nurses who visit patients  
46  
47 at home. Davison et al. [17] and Nicholson et al. [18] suggested the use of non-specialised  
48  
49 ‘generic’ community nursing teams for home supervision to increase the capacity of hospital-  
50  
51 at-home schemes.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The Netherlands has a nation-wide, good infrastructure for community nursing, which could  
4 be used for hospital-at-home. Therefore we designed an early assisted discharge hospital-at-  
5 home scheme for COPD exacerbations, mainly operated by generic community nurses who  
6 performed the home visits [19]. Main objective of the GO AHEAD study (GO AHEAD is the  
7 acronym for Assessment Of Going Home under Early Assisted Discharge) was to determine  
8 the effectiveness and cost-effectiveness of early assisted discharge followed by community-  
9 based nursing care at home. In addition, evaluation of patient satisfaction and preferences,  
10 carer strain and preferences and an evaluation among professional care providers was  
11 performed. The focus of this paper is on the effectiveness of early assisted discharge, with the  
12 Clinical COPD Questionnaire (CCQ) as the primary outcome measure. In addition, treatment  
13 failures, readmissions, mortality and generic quality of life were assessed as secondary  
14 outcomes.

## 31 **Methods**

32 GO AHEAD was a randomised controlled trial comparing usual hospital care with early  
33 assisted discharge for COPD exacerbations. Five hospitals and three home care organisations  
34 participated. Treatment consisted of seven days in-hospital care as usual or three days in-  
35 hospital treatment followed by four days care at home. Patients were followed until three  
36 months after randomisation.

37 All patients admitted to one of the participating hospitals with a COPD exacerbation, as  
38 diagnosed by the reviewing physician, were screened for potential eligibility on their first day  
39 of admission according to the inclusion and exclusion criteria (table 1). On day 3 of  
40 admission, clinical stability was assessed in patients who gave written informed consent (see  
41 randomisation criteria in table 1). For each hospital separately, participating patients were



randomised on day 3 of admission, in a 1:1 ratio using a block-size of 6. Randomisation was performed by the study nurses. The randomisation sequence was computer-generated a priori by an independent researcher. Allocation sequence was placed in sealed envelopes. The study was approved by the Ethics Committee of the Catharina Hospital, the Netherlands, approval number M07-1755.

**Table 1** Inclusion and exclusion criteria (applied at admission) and randomisation criteria (applied at day 3 of admission)

Inclusion criteria (checked on day 1)	Exclusion criteria (checked on day 1)
Age $\geq$ 40 years	Major uncontrolled comorbidity, including pneumonia that is prominent, heart failure that is prominent or acute changes on electrocardiogram and (suspected) underlying malignancy.
Competent to give informed consent	Mental disability, including dementia, impaired level of consciousness and acute confusion.
Diagnosed with COPD. COPD was defined as at least GOLD stage I and 10 pack years of smoking	Living outside care region of the home care organisation
Hospitalisation for COPD exacerbation	Inability to understand the program
	Indication for admission to intensive care unit or for non invasive ventilation
	Active alcohol and/or drug abuse
	Insufficient availability of informal care at

	home
<b>Randomisation criteria (checked on day 3)</b>	
Completed Informed Consent on day three of admission	
Acceptable general health: <ul style="list-style-type: none"> <li>- Decrease physical complaints</li> <li>- Non dependency of therapies that cannot be given at home (intravenous therapy and newly prescribed oxygen supply).</li> <li>- Being able to visit toilet independently</li> </ul>	
Normal or moderately increased blood sugar levels, defined as $\leq 15$ mmol/L or $\geq 15$ mmol/L but patient is capable to regulate blood sugar levels independently	
Respiratory complaints of dyspnoea, wheezing and rhonchi must have decreased in comparison with day of admission.	

During the first three days of the admission all patients were treated in the hospital according to the study protocol [19]. Treatment consisted of systemic corticosteroids, nebulised bronchodilators and antibiotics and oxygen upon indication. Exacerbation symptoms were scored each day. Physiotherapists visited all patients for instruction of breathing and coughing techniques. On the fourth day of admission all randomised patients switched to oral medication and metered dosed inhalations. Patients randomised to early assisted discharge were discharged home on the fourth day of admission and further treated at home.

Community nurses visited or contacted the patient at least once daily on the day of discharge and the three consecutive days. They continued to score exacerbation symptoms and provided reassurance and counselling. Furthermore, medication compliance and inhalation techniques were addressed. Community nurses had the highest levels of generic nursing training in the Netherlands. No additional training was provided for the trial. The nurses could contact the

1  
2  
3 hospital to discuss the patient's condition. If necessary, patients were readmitted to the  
4  
5 hospital. For patients a 24-hour telephone access to the hospital respiratory ward was installed  
6  
7 for emergencies.  
8  
9

10  
11 Patients in the usual hospital care group received care as usual at the discretion of the hospital  
12  
13 staff. General practitioners were informed about the patient's participation in the trial and the  
14  
15 discharge date. Clinical responsibility during home care remained with the respiratory  
16  
17 physician. A detailed description of the research protocol and the early assisted discharge  
18  
19 intervention has been published previously [19].  
20  
21  
22  
23

24  
25 Primary outcome was the change in CCQ scores between baseline (T0= day 3 of admission)  
26  
27 and the end of the supervised treatment (T+4 days). The CCQ is a disease-specific  
28  
29 questionnaire measuring health status [20]. It consists of 10 questions in three domains:  
30  
31 symptoms, functional state and mental state, resulting in a overall, continuous score varying  
32  
33 from 6 (worst score) to 0 (best score) [20]. In order to produce a valid overall score, 3, 3 and 2  
34  
35 questions on the symptoms domain, functional state and mental state domain, respectively  
36  
37 need to be answered. The CCQ has proved to be responsive to change. The minimal clinical  
38  
39 important difference is 0.4 [21]. Secondary outcomes were: 1) change in CCQ scores between  
40  
41 baseline and three months after randomisation (T+90 days); 2) number of treatment failures  
42  
43 (i.e. either death or clinical deterioration leading to prolonged hospital stay beyond the  
44  
45 standardised seven days (usual hospital care) or death or readmission during the four days  
46  
47 treatment at home (early discharge)); 3) mortality and 4) readmissions during the three month  
48  
49 follow-up; and 5) generic health-related quality of life measured by the EuroQol-5D (EQ-  
50  
51 5D)[22] at baseline, T+4 days and T+90 days. Utilities were calculated using the Dutch value  
52  
53 set [22]. Higher scores represent better generic quality of life.  
54  
55  
56  
57  
58  
59  
60

## Statistical analysis

To detect a difference of 0.4 in CCQ change scores between the two groups, in favour of the early discharge group, with a power of 0.80 and alpha of 0.05, with standard deviation in the usual hospital care group of 0.922 and 0.988 in the early discharge group, the required sample size was 165 [19]. Change in CCQ scores and EQ-5D scores was analysed using a linear repeated measures model with correlated errors. An unstructured covariance matrix for the residuals of the different measurements was used. Backward selection of covariates was applied. In addition to time (i.e. measurement at T+4 days, end of treatment, and T+90 days, end of follow-up), the interaction of time and treatment, the following variables were tested: baseline CCQ or EQ-5D score, treatment centre, age, gender, comorbidity, smoking status, living situation, availability informal caregiver, presence of home care prior to admission, course of oral corticosteroids and/or antibiotics prior to admission. Variables were retained in the model if their exclusion led to a 10% change in the estimated treatment effect [23]. For the analysis of CCQ scores, only baseline score was included in the final model. For the analysis of EQ-5D scores, baseline score, comorbidity and gender were included. Results are presented as mean differences in change and 95% confidence intervals (95% CI). Numbers of patients with treatment failures, readmissions and mortality were analysed using multiple logistic regression analysis. Numbers of readmissions per patient in each group were analysed in a Poisson regression. Time to readmission was analysed with a Cox proportional hazards model. Results are presented as odds ratios (OR) or hazard ratios (HR) with 95% CI. Again, backward selection was used to select covariates. Only baseline CCQ score was retained in the models. The significance level for a difference between treatment groups was set at  $p \leq 0.05$ . All analyses were performed using the Statistical Package for Social Sciences (SPSS), version 17.0, IBM.

## Results

In total, 1371 patients were screened for eligibility between November 2007 and March 2011, of whom 508 met the criteria for eligibility on day 1. Figure 1 shows an overview of the patient flow during the trial from hospital admission to the end of the follow-up. Three patients in the early assisted discharge group and 7 in the usual hospital care group were not satisfied with the allocated place of treatment and withdrew consent immediately after randomisation. The total dropout over the study period was 16%, 25% in the usual hospital care group and 10% in the early assisted discharge group. Baseline CCQ scores of patients dropping out were not different from those who completed the study, but they did have more comorbidities. At T+4 days 118 of 129 still participating patients produced a valid overall score on the CCQ and were included in the analysis. The other patients did not withdraw consent and continued to participate in the study in order to contribute to the other analyses and to produce a valid score at other measuring points. This approach fits with the intention-to-treat principle and the repeated measures analysis. At T+90 days, 101 of 115 patients produced a valid overall CCQ score.

Table 2 shows the baseline characteristics of randomised patients by treatment group. These were comparable across the groups. At end of the follow-up period lung function testing was performed by which classification of disease severity according to the GOLD criteria [2] could be made (see table 3).

**Figure 1** Patient flow through study.

**Table 2** Baseline characteristics and treatment at admission. Values represent mean (SD), unless stated otherwise.

Characteristic	Usual hospital care (N=69)	Early assisted discharge (N=70)
Age (years)	67.8 (11.3)	68.3 (10.3)
Men n (%)	38 (55.1)	48 (68.6)
<i>Smoking history:</i>		
Current smokers n (%)	27 (39.1)	23 (32.9)
Pack years, median	37	44
inter quartile range	36.9	26.7
Body Mass Index (kg/m <sup>2</sup> )	25.6 (4.3)	25.0 (5.1)
Charlson comorbidity score <sup>24,†</sup>	1.68 (1.1)	1.74 (1.1)
Comorbidity score of 1 n (%)	42 (60.0)	38 (54.0)
Comorbidity score > 1 n (%)	27 (39.0)	32 (46.0)
<i>Living situation:</i>		
Living alone n (%)	21 (30.4)	22 (31.4)
Receiving care at home before admission n (%)	16 (23.2)	17 (24.3)
<i>Treatment at admission:</i>		
Long term oxygen treatment n (%)	4 (5.8)	5 (7.1)
Oral steroids n (%)	5 (7.2)	10 (14.3)
Course of oral steroids prior to admission n (%)	34 (50.0)	35 (50.7)
Course antibiotics prior to admission n (%)	31 (45.6)	32 (46.4)
Inhaled $\beta$ 2-agonist (LABA) n (%)	9 (13.0)	7 (10.0)
Inhaled corticosteroid n (%)	3 (12.0)	3 (15.0)

Inhaled corticosteroid/LABA combination n (%)	44 (63.7)	50 (71.4)
Inhaled anticholinergic n (%)		
Tiotropium	31 (44.9)	36 (51.4)
Ipratropium	12 (17.4)	13 (18.6)
Followed rehabilitation program in year prior to admission n (%)	10 (14.9)	12 (17.4)
Heart Rate (beats/minute)	91.0 (14.2)	95.6 (18.4)
<i>Arterial blood gas</i> <sup>#</sup> :	N=37	N=42
pH	7.44 (0.05)	7.43 (0.04)
pO <sub>2</sub> (mmHg)	70.7 (13.2)	67.3 (8.1)
pCO <sub>2</sub> (mmHg)	37.2 (6.2)	39.1 (5.3)
Saturation	94 (2.5)	94 (3.6)

† Charlson Comorbidity Index, 1= only COPD, higher score means more comorbidities; # only data of blood gas measurements in patients without oxygen supplement; LABA: long acting beta2 agonist

**Table 3**

Lung function testing at end of 3 month follow-up. Values represent mean (SD), unless stated otherwise.

	Usual hospital care	Early assisted discharge
Postbronchodilator FEV <sub>1</sub> (litres)	1.25 (0.07)	1.21 (0.07)
% of predicted postbronchodilator FEV <sub>1</sub>	50.29 (2.71)	45.20 (2.13)
GOLD stage I, n (%)	7 (10.3)	2 (2.9)
GOLD stage II, n (%)	22 (32.4)	23 (32.9)
GOLD stage III, n (%)	28 (41.2)	31 (44.3)
GOLD stage IV, n (%)	11 (16.2)	14 (20.0)

Table 4 shows the unadjusted CCQ scores at the different measuring points. At T0 CCQ scores were 2.22 (0.97) for the usual hospital care group and 2.63 (1.06) for the early discharge group. Figure 2 shows the change in CCQ scores from T0, adjusted for baseline score. CCQ scores improved between T0 and T+4 days for the usual hospital care group, and were almost stable for the early assisted discharge group, but there was no significant difference between the groups at T+4 days (difference in mean change from T0 0.29, 95% CI -0.03 to 0.61, p=0.078). At T+90 days, CCQ scores of both groups were slightly higher in comparison to T0. There was no difference between the groups at three months (difference in mean change from T0 0.04, 95% CI -0.40 to 0.49, p=0.858).

**Table 4**

Unadjusted mean (SD) CCQ total scores at each time of measurement by treatment group.

Time of measurement	Usual hospital care	Early assisted discharge
T- 2 days	3.21 (1.07)	3.49 (1.07)
T0	2.22 (0.97)	2.63 (1.06)
T+ 4 days	2.00 (1.09)	2.55 (1.21)



T+ 90 days	2.41 (1.14)	2.70 (1.32)
------------	-------------	-------------

CCQ total score range is 0-6; 0 represents best possible score and 6 represents worst possible score

### Figure 2 CCQ total score, differences in mean change from baseline

Treatment failed in five patients. One patient in the early discharge group needed readmission to the hospital because of deterioration of respiratory symptoms, before the end of the home treatment and 4 patients in the usual hospital care group required hospital admission beyond the 7 days that were stated in the protocol (2 because of deterioration of respiratory symptoms, 2 patients because of deterioration of general condition due to gastroenteritis caused by norovirus). This difference was not significant (OR early discharge group 0.27, 95% CI 0.026 – 2.70,  $p=0.263$ ). Table 5 shows the number of readmissions during follow-up. Seventeen patients in each group had 1 or more readmission to the hospital of which 14 first readmissions were due to an exacerbation or other pulmonary indication (OR early discharge group 0.80, 95% CI 0.36 – 1.79,  $p=0.592$ ). There was no difference in the number of readmissions per patient between the groups, or in the total number of readmissions in each group. There was no difference in time to first readmission between the two groups (HR early discharge group 0.77, 95% CI 0.39 to 1.53,  $p=0.461$ ).

**Table 5** Readmissions during follow-up. Values are numbers of patients (%).

	Usual hospital care	Early assisted discharge
Patients with readmission	17 (25)	17 (24)
Patients with 1, 2 or $\geq 3$ readmissions		
1 readmission	11	12

2 readmissions	4	3
3 or more readmissions	2	2
Average (SD) time to first readmission in days	61 (36.5)	69 (33.8)

No patient died during the hospital or home treatment, but 1 patient from each group died during follow-up. Cause of death was unknown in one case (patient died during sleep at home) and an acute abdomen in the other. Both were not related to the trial.

EQ-5D utility scores (SD) at T0 were 0.713 (0.22) for the usual hospital care group and 0.664 (0.26) for the early assisted discharge group. Table 6 shows the mean changes and mean difference in change from baseline of EQ-5D utility. In the usual hospital care group, mean utility scores improved from T0 to T+4 days and decreased to baseline at T+90 days. In the early assisted discharge group mean utility scores remained close to baseline. The mean change in utility scores on T+4 days was significant greater in the usual hospital care group. At T+90 days this difference between treatment groups had disappeared.

**Table 6** Mean changes and mean differences in change for EQ-5D.

		Mean change from baseline (SE)		Adjusted mean (95% CI) difference in change from baseline*	p value
Utility		Usual hospital care	Early assisted discharge	Usual care - early discharge	
	T+ 4 days†	0.051 (0.0261)	-0.005 (0.029)	0.0746 (0.010 to 0.139)	0.024
	T+ 90 days‡	-0.036 (0.0447)	0.008 (0.039)	-0.022 (-0.116 to 0.072)	0.639

\*Results from repeated measures analysis, adjusted for baseline value † hospital care N=57, early discharge N=61; ‡ hospital care N=47, early discharge N=54  
SE: Standard Error; 95% CI: 95% Confidence Interval

## Discussion

This is the first randomised controlled trial that investigated the effectiveness of early assisted discharge for COPD exacerbations with supervision at home by community nurses. In addition, this is the first evaluation of early discharge for this disease in the Dutch health care system. While patients' disease-specific health status as expressed in the mean CCQ score after seven days treatment tended to be somewhat better in the usual hospital care group, the difference was small, not clinically relevant and not statistically significant. After three months, the difference had disappeared. The same pattern was found in generic health-related quality of life measured with the EQ-5D, although this difference was statistically significant at the end of the supervised treatment. The difference had disappeared at the end of the 3-month follow up period. There was no difference in treatment failures, readmissions or mortality.

1  
2  
3 These study results confirm previously published positive results by Davison et al. [17] and  
4  
5 Nicholson et al. [18], but these two studies were either not randomised [17] or included a  
6  
7 small number of patients [18]. We found no significant difference in CCQ scores, which  
8  
9 corresponds with the findings of Davies et al. [9] and Hernandez et al. [16], who found no  
10  
11 differences in disease-specific quality of life measured with the St George's Respiratory  
12  
13 Questionnaire. Furthermore, our results are in line with those of earlier studies involving  
14  
15 specialised hospital-based nurses [9-12,15,16,24,25]. The readmission rate in our study was  
16  
17 25%, which is comparable to the 30% in previously published studies [9-11]. Characteristics  
18  
19 like age, smoking history and living situation of patients in our study were similar to those in  
20  
21 studies from the United Kingdom [9-12] and to that of a survey on hospital-at-home services  
22  
23 in British hospitals by Quantrill et al. [26].  
24  
25  
26  
27  
28

29  
30 Earlier studies did not measure the impact of hospital-at-home on generic health-related  
31  
32 quality of life. We found a significant difference between the two groups, in favour of usual  
33  
34 hospital care, at the end of the hospital and home treatment. This difference had disappeared  
35  
36 after three months. The utility scores are in line with O'Reilly et al. [27], but they found  
37  
38 much worse scores at admission than in our study, probably because we did not include  
39  
40 patients with more severe exacerbations. Utility and CCQ scores in both groups follow the  
41  
42 same pattern. The greater improvement in CCQ and EQ-5D scores of the usual hospital care  
43  
44 group at the end of the hospital treatment in comparison to the early discharge group may  
45  
46 reflect a true difference in recovery, in which case usual hospital care is the preferred  
47  
48 treatment. However, an alternative explanation could be that patients who were discharged  
49  
50 early were confronted with their symptoms and limitations earlier and more intensely when  
51  
52 they tried to pick up normal life at home. Furthermore, some patients have difficulties  
53  
54 viewing hospital care followed by early discharge as one treatment period [28]. Expecting to  
55  
56  
57  
58  
59  
60

1  
2  
3 be in a certain state at discharge, and experiencing this is not the case, might be expressed in  
4  
5 worse scores on the CCQ and the EQ-5D.  
6  
7

8  
9  
10 In our trial multiple hospitals participated with different socioeconomic and geographic  
11 characteristics, which makes it likely that our sample is representative of eligible patients. The  
12 percentage of admissions initially considered to be eligible for early discharge at admission  
13 was similar to that of previous studies ( $\pm 37\%$ ). Early discharge is possible when the  
14 exacerbation is the main problem and comorbidities are (relatively) stable. The percentage of  
15 patients living alone suggests that this is not an absolute reason for exclusion, provided that  
16 patients have a sufficiently functioning social support system. Still, 25% of screened patients  
17 were considered ineligible, because of living in a nursing home, overburden of informal  
18 caregiver(s) or living alone with insufficient social support. This suggests that social  
19 environment is an important factor when deciding for admission and (early) discharge.  
20  
21 Finally, 37% of screened patients was ineligible because of comorbidities.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Considering the very low number of treatment failures in the early discharge group it might be  
37 possible to relax the inclusion criteria and randomisation criteria. In our trial, criteria were  
38 applied very strictly for safety reasons, but more patients with comorbidities might be eligible  
39 in daily practice. Furthermore, the strict review and exclusion of patients at day 1 of  
40 admission (e.g. those treated with NIV), precluded patients from early discharge even if they  
41 had become eligible at day 3 of admission. Therefore, review of eligibility for early discharge  
42 should be performed after a few days of hospital treatment. Thirty percent of patients who  
43 consented to participate were not randomised because they showed insufficient recovery  
44 and/or were depending on oxygen supply. Unlike in the British hospital-at-home schemes,  
45 patients were not sent home with nebulisers or oxygen cylinders, unless these were already  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 part of their treatment. Extension of the treatment possibilities at home may enable early  
4  
5 discharge of patient with more severe disease. However, it would also require more expertise  
6  
7 of the nursing staff supervising patients at home, which might currently not be present in  
8  
9 community-based home care organisations. Future research should focus on determining  
10  
11 which treatments can be safely provided at home, which treatments require the supervision of  
12  
13 generic or specialised nurses and which criteria should be applied for selecting eligible  
14  
15 patients. In addition, a direct comparison between early discharge with generic and early  
16  
17 discharge with specialised nursing care would provide more information on which scheme is  
18  
19 most safe and effective.  
20  
21  
22  
23  
24

25 Our study has some limitations. Firstly, in total 139 patients were randomised, where a  
26  
27 number of 165 was calculated to be needed to detect a difference of 0.4 in CCQ change scores  
28  
29 between the two groups. A post-hoc power analysis with these 139 patients and the actual  
30  
31 variances in CCQ scores showed that the power to detect a difference in change from baseline  
32  
33 of 0.4 between the groups was 73% instead of 80%, which was aimed for. We believe that  
34  
35 this slight reduction in power does not have a substantial influence on our final results,  
36  
37 because the difference between the groups was only 0.29. It is highly unlikely that this  
38  
39 difference would have increased to the clinically relevant difference of 0.4 with an additional  
40  
41 26 patients. In previous randomised studies of early discharge in patients diagnosed with  
42  
43 COPD numbers varied between 25 and 222, and only 15 to 35% of admitted patients was  
44  
45 randomised [9-12,16,29]. Secondly, our study was not an equivalence trial, which would  
46  
47 determine best whether hospital care and early discharge care are equally effective. However,  
48  
49 in order to demonstrate equal effectiveness with CCQ score, over 500 patients would have  
50  
51 been needed, which is beyond what is attainable in this population. Thirdly, 16% of patients  
52  
53 dropped out after randomisation. However, comparison of patients who dropped out with  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 patients who completed the study only revealed more comorbidities for those who dropped  
4  
5 out. CCQ scores were not different. Fourthly, although our variable selection for the analyses  
6  
7 is justifiable, treatment centre could also be considered as an important covariate in the  
8  
9 analyses, based on the randomisation design of the study. However, adding treatment centre  
10  
11 as additional fixed factor to the analyses did not result in different outcomes in any of the  
12  
13 analyses. It was therefore omitted and the analyses remained unchanged. Finally, due to the  
14  
15 nature of the intervention, patients and health care staff could not be blinded to the allocated  
16  
17 group.  
18  
19

20  
21  
22  
23 In conclusion, we found no significant short-term or long-term differences in outcomes  
24  
25 between early discharge and usual hospital care, except for generic health-related quality of  
26  
27 life at the end of treatment (T+4 days). Early assisted discharge with home visits by  
28  
29 community nurses can reduce length of hospital stay for a selected group of patients admitted  
30  
31 with a COPD exacerbation and is an alternative to usual hospital care. The decision to  
32  
33 implement early assisted discharge with community nursing does not only depend on the  
34  
35 results of the effectiveness analysis. Costs and cost-effectiveness evaluations are of high  
36  
37 importance as well. An economic evaluation is currently being performed and results will be  
38  
39 published separately.  
40  
41  
42  
43  
44

### 45 **Funding**

46  
47 The study was funded by the Netherlands Organisation for Health Research and Development  
48  
49 (ZonMw), grant application number 945-50-7730. The funder had no role in the design of the  
50  
51 study; the collection analysis and interpretation of the data; or the writing of the article and  
52  
53 the decision to submit the article for publication. All researchers were independent from the  
54  
55 funder.  
56  
57  
58  
59  
60

### Copyright/licence for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a **worldwide licence** to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.”

### Competing interests

“All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare that (1) LG, MR, OvS have had support from ZonMw for the submitted work; (2) CU, FS, MvV, MB, LvE have no relationships with companies that might have an interest in the submitted work in the previous 3 years; LG and MR have relationships (received grants to perform cost- and cost-effectiveness studies) from multiple pharmaceutical companies, OvS has relationships (consultancy) with Pfizer, Boehringer Ingelheim and Astra Zeneca that might have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or children have [specified] financial relationships that may be relevant to the submitted work; and (4) CU, LG, FS, MR, MvV, MB, LvE and OvS have no non-financial interests that may be relevant to the submitted work.”



### Contributors

CU was involved in patient recruitment, database management, administration of questionnaires, data analysis, data interpretation and wrote the manuscript. LG was involved in data analysis and data interpretation and preparation of the manuscript. FS was local coordinating physician and involved in data interpretation and preparation of the manuscript. MR designed the study and involved in data interpretation and preparation of the manuscript. MvV was local coordinating physician in the Atrium Medical Centre and involved in the preparation of the manuscript. MB and LvE were coordinators of the home care organisations and involved in the preparation of the manuscript. OvS designed the study and was involved in data interpretation and writing the manuscript. OvS is guarantor for the study. All researchers had access to all data.

### Acknowledgements

The authors thank all care professionals from the participating hospitals and home care organisations that made the trial and early assisted discharge possible: W. van Litsenburg (Catharina-hospital), A. Janssen (Catharina-hospital), W. Seezink (Atrium Medical Centre), B. van de Pas (Máxima Medical Centre), A. van der Pouw (Rijnstate Hospital) and P. de Laat (TweeSteden Hospital) who performed patient recruitment; R. Eijsermans who coordinated the home care visits in the Tilburg region; D. DeMunck (Máxima Medical Centre), J. Retera (TweeSteden Hospital) and P. de Bruijn (Rijnstate Hospital) who were responsible pulmonologists in the participating hospitals. We thank K. van der Meer, research assistant, for her assistance in the data input.

### Data sharing

No additional data available

## References

1. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007;370:741-750.
2. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;176:532-555.
3. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J* 2006;27:397-412.
4. Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;157:1418-1422.
5. Donaldson GC, Seemungal TA, Bhowmik A et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002;57:847-852.
6. Esteban C, Quintana JM, Moraza J et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. *Respir Med* 2009;103:1201-1208.
7. Toy EL, Gallagher KF, Stanley EL et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. *COPD* 2010;7:214-228.
8. Jordan RE, Hawker JI, Ayres JG et al. Effect of social factors on winter hospital admission for respiratory disease: a case-control study of older people in the UK. *Br J Gen Pract* 2008;58:400-402.

- 1  
2  
3 9. Davies L, Wilkinson M, Bonner S et al. "Hospital at home" versus hospital care in  
4 patients with exacerbations of chronic obstructive pulmonary disease: prospective  
5 randomised controlled trial. *BMJ* 2000;321:1265-1268.  
6  
7
- 8  
9  
10 10. Cotton MM, Bucknall CE, Dagg KD et al. Early discharge for patients with  
11 exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.  
12 *Thorax* 2000;55:902-906.  
13  
14
- 15  
16 11. Skwarska E, Cohen G, Skwarski KM et al. Randomized controlled trial of supported  
17 discharge in patients with exacerbations of chronic obstructive pulmonary disease.  
18 *Thorax* 2000;55:907-912.  
19  
20
- 21  
22 12. Ojoo JC, Moon T, McGlone S et al. Patients' and carers' preferences in two models of  
23 care for acute exacerbations of COPD: results of a randomised controlled trial. *Thorax*  
24 2002;57:167-169.  
25  
26
- 27  
28 13. British Thoracic Society. Intermediate care--Hospital-at-Home in chronic obstructive  
29 pulmonary disease: British Thoracic Society guideline. *Thorax* 2007;62:200-210.  
30  
31
- 32  
33 14. Diaz LS, Gonzalez LF, Gomez Mendieta MA et al. [Evaluation of a home  
34 hospitalization program in patients with exacerbations of chronic obstructive  
35 pulmonary disease]. *Arch Bronconeumol* 2005;41:5-10.  
36  
37
- 38  
39 15. Grivil JH, Al-Rawas OA, Cotton MM et al. Home treatment of exacerbations of  
40 chronic obstructive pulmonary disease by an acute respiratory assessment service.  
41 *Lancet* 1998;351:1853-1855.  
42  
43
- 44  
45 16. Hernandez C, Casas A, Escarrabill J et al. Home hospitalisation of exacerbated chronic  
46 obstructive pulmonary disease patients. *Eur Respir J* 2003;21:58-67.  
47  
48
- 49  
50 17. Davison AG, Monaghan M, Brown D et al. Hospital at home for chronic obstructive  
51 pulmonary disease: an integrated hospital and community based generic intermediate  
52 care service for prevention and early discharge. *Chron Respir Dis* 2006;3:181-185.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 18. Nicholson C, Bowler S, Jackson C et al. Cost comparison of hospital- and home-based  
4  
5 treatment models for acute chronic obstructive pulmonary disease. *Aust Health Rev*  
6  
7 2001;24:181-187.  
8
- 9  
10 19. Utens CM, Goossens LM, Smeenk FW et al. Effectiveness and cost-effectiveness of  
11  
12 early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the  
13  
14 design of a randomised controlled trial. *BMC Public Health* 2010;10:618  
15
- 16 20. van der Molen T, Willemse BW, Schokker S et al. Development, validity and  
17  
18 responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes*  
19  
20 2003;1:13  
21
- 22 21. Kocks JW, Tuinenga MG, Uil SM et al. Health status measurement in COPD: the  
23  
24 minimal clinically important difference of the clinical COPD questionnaire. *Respir*  
25  
26 *Res* 2006;7:62  
27  
28
- 29 22. Lamers LM, McDonnell J, Stalmeier PF et al. The Dutch tariff: results and arguments  
30  
31 for an effective design for national EQ-5D valuation studies. *Health Econ*  
32  
33 2006;15:1121-1132.  
34  
35
- 36 23. Rothman KJ, Greenland S, Lash TL. *Modern Epidemiology* (3rd edition).  
37  
38 Philadelphia: Lippincott Williams & Wilkins 2008.  
39
- 40 24. Ansari K, Shamssain M, Farrow M et al. Hospital-at-home care for exacerbations of  
41  
42 chronic obstructive pulmonary disease: an observational cohort study of patients  
43  
44 managed in hospital or by nurse practitioners in the community. *Chron Respir Dis*  
45  
46 2009;6:69-74.  
47  
48
- 49 25. Sala E, Alegre L, Carrera M et al. Supported discharge shortens hospital stay in  
50  
51 patients hospitalized because of an exacerbation of COPD. *Eur Respir J* 2001;17:1138-  
52  
53 1142.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 26. Quantrill SJ, Lowe D, Hosker HS et al. Survey of early discharge schemes from the  
4  
5 2003 UK National COPD Audit. *Respir Med* 2007;101:1026-1031.  
6  
7 27. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with  
8  
9 COPD exacerbation managed in hospital. *Int J Clin Pract* 2007;61:1112-1120.  
10  
11 28. Clarke A, Sohanpal R, Wilson G et al. Patients' perceptions of early supported  
12  
13 discharge for chronic obstructive pulmonary disease: a qualitative study. *Qual Saf*  
14  
15 *Health Care* 2010;19:95-98.  
16  
17 29. Aimonino RN, Tibaldi V, Leff B et al. Substitutive "hospital at home" versus inpatient  
18  
19 care for elderly patients with exacerbations of chronic obstructive pulmonary disease:  
20  
21 a prospective randomized, controlled trial. *J Am Geriatr Soc* 2008;56:493-500.  
22  
23 30. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic  
24  
25 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*  
26  
27 1987;40:373-383  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Title:**

Early assisted discharge with generic community nursing for Chronic Obstructive Pulmonary  
Disease exacerbations: results of a randomised controlled trial

Cecile MA Utens<sup>1,2</sup>, Lucas MA Goossens<sup>3</sup>, Frank WJM Smeenk<sup>1</sup>, Maureen PMH Rutten-van  
Mölken<sup>3</sup>, Monique van Vliet<sup>4</sup>, Maria W Braken<sup>5</sup>, Loes MGA van Eijnsden<sup>6</sup>, Onno CP van  
Schayck<sup>2</sup>

**Affiliations:**

<sup>1</sup>Department of Respiratory Medicine, Catharina-hospital Eindhoven, Eindhoven, the  
Netherlands, P.O. Box 1350 ZA Eindhoven, the Netherlands

<sup>2</sup>Department of General Practice, CAPHRI School for Public Health and Primary Care,  
Maastricht University, Maastricht, the Netherlands, P.O. box 616 6200 MD Maastricht, the  
Netherlands

Cecile MA Utens

PhD candidate

<sup>3</sup>Institute for Medical Health Technology Assessment, Erasmus University, Rotterdam, the  
Netherlands, P.O. box 1738 3000 DR Rotterdam, the Netherlands

Lucas MA Goossens

Researcher/ PhD candidate

<sup>1</sup>Department of Respiratory Medicine, Catharina-hospital Eindhoven, Eindhoven, the  
Netherlands, P.O. Box 1350 ZA Eindhoven, the Netherlands

Frank WJM Smeenk

1  
2  
3 Pulmonologist  
4  
5  
6

7 <sup>3</sup>Institute for Medical Health Technology Assessment, Erasmus University, Rotterdam, the  
8 Netherlands, P.O. box 1738 3000 DR Rotterdam, the Netherlands  
9

10  
11 Maureen PMH Rutten-van Mólken

12  
13  
14 Professor  
15  
16

17  
18 <sup>4</sup>Department of Respiratory Medicine, Atrium Medical Centre, Heerlen, the Netherlands, P.O.  
19 box 4446 6401 CZ Heerlen, the Netherlands  
20

21  
22 Monique van Vliet

23  
24  
25 Pulmonologist  
26  
27

28  
29 <sup>5</sup>Department of Staff nurses Nursing and Care, ZuidZorg, Veldhoven, the Netherlands, P.O.  
30 box 2160 5500 BD Veldhoven, the Netherlands  
31

32  
33  
34 Maria Braken

35  
36  
37 Staff nurse  
38  
39

40  
41 <sup>6</sup>Department of Health Care Policy, Meander Group Zuid-Limburg, Heerlen, the Netherlands  
42 P.O. box 2690 6401 DD Heerlen, the Netherlands  
43

44  
45  
46 Loes van Eijnsden

47  
48  
49 Policy officer  
50

51  
52 <sup>2</sup>Department of General Practice, CAPHRI School for Public Health and Primary Care,  
53 Maastricht University, Maastricht, the Netherlands, P.O. box 616 6200 MD Maastricht, the  
54 Netherlands  
55  
56  
57  
58  
59  
60

1  
2  
3 Onno CP van Schayck

4  
5 Professor

6  
7  
8  
9 **Corresponding author:**

10  
11 Cecile Utens

12  
13 Email: [cecileutens@gmail.com](mailto:cecileutens@gmail.com)

14  
15  
16  
17  
18 **Keywords:** Hospital at home; Early assisted discharge from hospital; Chronic Obstructive  
19  
20 Pulmonary Disease; Community nursing, Randomised controlled trial  
21  
22

23  
24  
25 **Abstract**

26  
27 **Objectives:** To determine effectiveness of early assisted discharge [for COPD exacerbations](#),  
28  
29 with home care provided by generic community nurses, compared to usual hospital care.  
30

31  
32 Design: Prospective, randomised controlled, multi-centre trial with 3 months follow-up.

33  
34 **Setting:** Five hospitals and 3 home care organisations in the Netherlands.

35  
36 **Participants:** Patients admitted to the hospital with an exacerbation of Chronic Obstructive  
37  
38 Pulmonary Disease. Patients with no or limited improvement of respiratory symptoms and  
39  
40 patients with severe unstable comorbidities, social problems or those unable to visit the toilet  
41  
42 independently were excluded.  
43

44  
45 **Intervention:** Early discharge from hospital after 3 days inpatient treatment. Home visits by  
46  
47 generic community nurses. Primary outcome measure was change in health status measured  
48  
49 by the Clinical COPD Questionnaire (CCQ). Treatment failures, readmissions, mortality and  
50  
51 change in generic health-related quality of life (HRQL) were secondary outcome measures.  
52

53  
54 **Results:** 139 patients were randomised. No difference between groups was found in change in  
55  
56 CCQ score at day 7 (difference in mean change 0.29 (95% CI -0.03 to 0.61)) or at 3 months  
57  
58  
59  
60



(difference in mean change 0.04 (95% CI -0.40 to 0.49)). No difference was found in secondary outcomes. At day 7 there was a significant difference in change in generic HRQL, favouring usual hospital care.

**Conclusion:** While patients' disease-specific health status after seven days treatment tended to be somewhat better in the usual hospital care group, the difference was small and not clinically relevant or statistically significant. After three months, the difference had disappeared. A significant difference in generic health-related quality of life at the end of the treatment had disappeared after 3 months and there was no difference in treatment failures, readmissions or mortality. Early assisted discharge with community nursing is feasible and an alternative to usual hospital care for selected patients with an acute COPD exacerbation  
~~COPD.~~

**Trial registration:** NetherlandsTrialRegister NTR 1129

### Article summary

Article focus:

- What is the effectiveness of early assisted discharge with community nursing for COPD exacerbations in comparison to usual hospital care as measured by the Clinical COPD Questionnaire.

Key Messages:

- There is no short term or long term difference in change in health status as measured by the Clinical COPD Questionnaire.

- A significant difference in generic health-related quality of life at the end of the treatment disappeared after 3 months.

1  
2  
3 - Early assisted discharge with home visits by community nurses is a feasible and an  
4  
5 alternative to usual hospital care for selected patients with an acute exacerbation of their  
6  
7 COPD.

8  
9 Strength and limitations:

10  
11 - 139 patients were randomised where 165 was calculated to be the required sample size.

12  
13 However, because the difference between the groups was only 0.29 instead of 0.4 it is  
14  
15 unlikely that this difference would have increased to the clinically relevant difference of 0.4  
16  
17 with an additional 26 patients.

18  
19 - This study is the first larger randomised controlled trial on early assisted discharge in the  
20  
21 Dutch health care system  
22  
23  
24  
25  
26

## 27 **Introduction**

28  
29 Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with high prevalence  
30  
31 [1], mortality and morbidity [2,3]. Exacerbations of the disease have negative effects on  
32  
33 patient outcomes [4-6] and are the main cause for hospitalisation [7]. Hospitalisations are not  
34  
35 only the main cost driver in COPD, they also put pressure on scarce hospital beds, especially  
36  
37 during winters [8]. Several studies have shown that some patients with an exacerbation, who  
38  
39 would otherwise be admitted to the hospital, can be treated at home safely after examination  
40  
41 in the emergency department or a short hospital admission [9-16]. This is called hospital-at-  
42  
43 home. Hospital-at-home aims to avoid admission, or reduce length of stay (early assisted  
44  
45 discharge schemes). Previous studies found no differences in readmissions, mortality and  
46  
47 disease-specific quality of life between hospital-at-home and usual hospital care [9-11,15,16].  
48  
49 Most published hospital-at-home studies originate from the United Kingdom and Spain,  
50  
51 where this service is mainly provided by hospital-based respiratory nurses who visit patients  
52  
53 at home. Davison et al. [17] and Nicholson et al. [18] suggested the use of non-specialised  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 'generic' community nursing teams for home supervision to increase the capacity of hospital-  
4  
5 at-home schemes.  
6  
7

8  
9  
10 The Netherlands has a nation-wide, good infrastructure for community nursing, which could  
11  
12 be used for hospital-at-home. Therefore we designed an early assisted discharge hospital-at-  
13  
14 home scheme for COPD exacerbations, mainly operated by generic community nurses who  
15  
16 performed the home visits [19]. Main objective of the GO AHEAD study (GO AHEAD is the  
17  
18 acronym for Assessment Of Going Home under Early Assisted Discharge) was to determine  
19  
20 the effectiveness and cost-effectiveness of early assisted discharge followed by community-  
21  
22 based nursing care at home. In addition, evaluation of patient satisfaction and preferences,  
23  
24 carer strain and preferences and an evaluation among professional care providers was  
25  
26 performed. The focus of this paper is on the effectiveness of early assisted discharge, with the  
27  
28 Clinical COPD Questionnaire (CCQ) as the primary outcome measure. In addition, treatment  
29  
30 failures, readmissions, mortality and generic quality of life were assessed as secondary  
31  
32 outcomes.  
33  
34  
35  
36  
37

### 38 **Methods**

39  
40 GO AHEAD was a randomised controlled trial comparing usual hospital care with early  
41  
42 assisted discharge for COPD exacerbations. Five hospitals and three home care organisations  
43  
44 participated. Treatment consisted of seven days in-hospital care as usual or three days in-  
45  
46 hospital treatment followed by four days care at home. Patients were followed until three  
47  
48 months after randomisation.  
49  
50  
51

52  
53  
54 All patients admitted to one of the participating hospitals with a COPD exacerbation, as  
55  
56 diagnosed by the reviewing physician, were screened for potential eligibility on their first day  
57  
58  
59  
60

of admission according to the inclusion and exclusion criteria (table 1). On day 3 of admission, clinical stability was assessed in patients who gave written informed consent (see randomisation criteria in table 1). For each hospital separately, participating patients were randomised on day 3 of admission, in a 1:1 ratio using a block-size of 6. Randomisation was performed by the study nurses. The randomisation sequence was computer-generated a priori by an independent researcher. Allocation sequence was placed in sealed envelopes. The study was approved by the Ethics Committee of the Catharina Hospital, the Netherlands, approval number M07-1755.

**Table 1** Inclusion and exclusion criteria (applied at admission) and randomisation criteria (applied at day 3 of admission)

Inclusion criteria (checked on day 1)	Exclusion criteria (checked on day 1)
Age $\geq$ 40 years	Major uncontrolled comorbidity, <u>including pneumonia that is prominent, heart failure that is prominent or acute changes on electrocardiogram and (suspected) underlying malignancy.</u>
Competent to give informed consent	Mental disability, <u>including dementia, impaired level of consciousness and acute confusion.</u>
Diagnosed with COPD. <u>COPD was defined as</u> at least GOLD stage I and 10 pack years of smoking	Living outside care region of the home care organisation
Hospitalisation for COPD exacerbation	Inability to understand the program

	Indication for admission to intensive care unit or for non invasive ventilation
	Active alcohol and/or drug abuse
	Insufficient availability of informal care at home
<b>Randomisation criteria (checked on day 3)</b>	
Completed Informed Consent on day three of admission	
Acceptable general health: <ul style="list-style-type: none"> <li>- Decrease physical complaints</li> <li>- Non dependency of therapies that cannot be given at home (<u>intravenous therapy and newly prescribed oxygen supply</u>).</li> <li>- Being able to visit toilet independently</li> </ul>	
Normal or moderately increased blood sugar levels, defined as $\leq 15$ mmol/L or $\geq 15$ mmol/L but patient is capable to regulate blood sugar levels independently	
Respiratory complaints of dyspnoea, wheezing and rhonchi must have decreased in comparison with day of admission.	

During the first three days of the admission all patients were treated in the hospital according to the study protocol [19]. Treatment consisted of systemic corticosteroids, nebulised bronchodilators and antibiotics and oxygen upon indication. Exacerbation symptoms were scored each day. Physiotherapists visited all patients for instruction of breathing and coughing techniques. On the fourth day of admission all randomised patients switched to oral medication and metered dosed inhalations. Patients randomised to early assisted discharge were discharged home on the fourth day of admission and further treated at home.

Community nurses visited or contacted the patient at least once daily on the day of discharge

1  
2  
3 and the three consecutive days. They continued to score exacerbation symptoms and provided  
4  
5 reassurance and counselling. Furthermore, medication compliance and inhalation techniques  
6  
7 were addressed. Community nurses had the highest levels of generic nursing training in the  
8  
9 Netherlands. No additional training was provided for the trial. The nurses could contact the  
10  
11 hospital to discuss the patient's condition. If necessary, patients were readmitted to the  
12  
13 hospital. For patients a 24-hour telephone access to the hospital respiratory ward was installed  
14  
15 for emergencies.  
16  
17  
18  
19

20  
21 Patients in the usual hospital care group received care as usual at the discretion of the hospital  
22  
23 staff. General practitioners were informed about the patient's participation in the trial and the  
24  
25 discharge date. Clinical responsibility during home care remained with the respiratory  
26  
27 physician. A detailed description of the research protocol and the early assisted discharge  
28  
29 intervention has been published previously [19].  
30  
31  
32  
33

34  
35 Primary outcome was the change in CCQ scores between baseline (T0= day 3 of admission)  
36  
37 and the end of the supervised treatment (T+4 days). The CCQ is a disease-specific  
38  
39 questionnaire measuring health status [20]. It consists of 10 questions in three domains:

40  
41 symptoms, functional state and mental state, resulting in a overall continuous score varying  
42  
43 from 6 (worst score) to 0 (best score) [20]. In order to produce a valid overall score, 3, 3 and 2  
44  
45 questions on the symptoms domain, functional state and mental state domain, respectively  
46  
47 need to be answered. The CCQ has proved to be responsive to change. The minimal clinical  
48  
49 important difference is 0.4 [21]. ~~To detect a difference of 0.4 in CCQ change scores between~~  
50  
51 ~~the two groups, in favour of the early discharge group, with a power of 0.80 and alpha of 0.05,~~  
52  
53 ~~the required sample size was 165 [19].~~ Secondary outcomes were: 1) change in CCQ scores  
54  
55 between baseline and three months after randomisation (T+90 days); 2) number of treatment  
56  
57  
58  
59  
60

1  
2  
3 failures (i.e. either death or clinical deterioration leading to prolonged hospital stay beyond  
4 the standardised seven days (usual hospital care) or death or readmission during the four days  
5 treatment at home (early discharge)); 3) mortality and 4) readmissions during the three month  
6 follow-up; and 5) generic health-related quality of life measured by the EuroQol-5D (EQ-  
7 5D)[22] at baseline, T+4 days and T+90 days. Utilities were calculated using the Dutch value  
8 set [22]. Higher scores represent better generic quality of life.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **Statistical analysis**

20  
21 To detect a difference of 0.4 in CCQ change scores between the two groups, in favour of the  
22 early discharge group, with a power of 0.80 and alpha of 0.05, with standard deviation in the  
23 usual hospital care group of 0.922 and 0.988 in the early discharge group, the required sample  
24 size was 165 [19]. Change in CCQ scores and EQ-5D scores was analysed using a linear  
25 repeated measures model with correlated errors. An unstructured covariance matrix for the  
26 residuals of the different measurements was used. Backward selection of covariates was  
27 applied. In addition to time (i.e. measurement at T+4 days, end of treatment, and T+90 days,  
28 end of follow-up), the interaction of time and treatment, the following variables were tested:  
29 baseline CCQ or EQ-5D score, treatment centre, age, gender, comorbidity, smoking status,  
30 living situation, availability informal caregiver, presence of home care prior to admission,  
31 course of oral corticosteroids and/or antibiotics prior to admission. Variables were retained in  
32 the model if their exclusion led to a 10% change in the estimated treatment effect [23]. For the  
33 analysis of CCQ scores, only baseline score was included in the final model. For the analysis  
34 of EQ-5D scores, baseline score, comorbidity and gender were included. Results are presented  
35 as mean differences in change and 95% confidence intervals (95% CI). Numbers of patients  
36 with treatment failures, readmissions and mortality were analysed using multiple logistic  
37 regression analysis. Numbers of readmissions per patient in each group were analysed in a  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Poisson regression. Time to readmission was analysed with a Cox proportional hazards  
4  
5 model. Results are presented as odds ratios (OR) or hazard ratios (HR) with 95% CI. Again,  
6  
7 backward selection was used to select covariates. Only baseline CCQ score was retained in  
8  
9 the models. The significance level for a difference between treatment groups was set at  
10  
11  $p \leq 0.05$ . All analyses were performed using the Statistical Package for Social Sciences (SPSS),  
12  
13 version 17.0, IBM.  
14  
15  
16  
17  
18  
19  
20

## 21 Results

22  
23 In total, 1371 patients were screened for eligibility between November 2007 and March 2011,  
24  
25 of whom 508 met the criteria for eligibility on day 1. Figure 1 shows an overview of the  
26  
27 patient flow during the trial from hospital admission to the end of the follow-up. Three  
28  
29 patients in the early assisted discharge group and 7 in the usual hospital care group were not  
30  
31 satisfied with the allocated place of treatment and withdrew consent immediately after  
32  
33 randomisation. The total dropout over the study period was 16%, 25% in the usual hospital  
34  
35 care group and 10% in the early assisted discharge group. Baseline CCQ scores of patients  
36  
37 dropping out were not different from those who completed the study, but they did have more  
38  
39 comorbidities. At T+4 days 118 of 129 still participating patients produced a valid overall  
40  
41 score on the CCQ and were included in the analysis. The other patients did not withdraw  
42  
43 consent and continued to participate in the study in order to contribute to the other analyses  
44  
45 and to produce a valid score at other measuring points. This approach fits with the intention-  
46  
47 to-treat principle and the repeated measures analysis. At T+90 days, 101 of 115 patients  
48  
49 produced a valid overall CCQ score.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 2 shows the baseline characteristics of randomised patients by treatment group. These were comparable across the groups. At end of the follow-up period lung function testing was performed by which classification of disease severity according to the GOLD criteria [2]

could be made ([see table 3](#) supplementary data file 1).

**Figure 1** Patient flow through study.

**Table 2** Baseline characteristics and treatment at admission. Values represent mean (SD), unless stated otherwise.

Characteristic	Usual hospital care (N=69)	Early assisted discharge (N=70)
Age (years)	67.8 (11.3)	68.3 (10.3)
Men <u>n</u> (%)	38 (55.1)	48 (68.6)
<i>Smoking history:</i>		
Current smokers <u>n</u> (%)	27 (39.1)	23 (32.9)
Pack years, median	37	44
inter quartile range	36.9	26.7
Body Mass Index (kg/m <sup>2</sup> )	25.6 (4.3)	25.0 (5.1)
Charlson comorbidity score <sup>24,†</sup>	1.68 (1.1)	1.74 (1.1)
Comorbidity score of 1 <u>n</u> (%)	42 (60.0)	38 (54.0)
Comorbidity score > 1 <u>n</u> (%)	27 (39.0)	32 (46.0)
<i>Living situation:</i>		
Living alone <u>n</u> (%)	21 (30.4)	22 (31.4)
Receiving care at home before admission <u>n</u> (%)	16 (23.2)	17 (24.3)
<i>Treatment at admission:</i>		

Long term oxygen treatment <u>n</u> (%)	4 (5.8)	5 (7.1)
Oral steroids <u>n</u> (%)	5 (7.2)	10 (14.3)
Course of oral steroids prior to admission <u>n</u> (%)	34 (50.0)	35 (50.7)
Course antibiotics prior to admission <u>n</u> (%)	31 (45.6)	32 (46.4)
Inhaled $\beta$ 2-agonist (LABA) <u>n</u> (%)	9 (13.0)	7 (10.0)
Inhaled corticosteroid <u>n</u> (%)	3 (12.0)	3 (15.0)
Inhaled corticosteroid/LABA combination <u>n</u> (%)	44 (63.7)	50 (71.4)
Inhaled anticholinergic <u>n</u> (%)		
Tiotropium	31 (44.9)	36 (51.4)
Ipratropium	12 (17.4)	13 (18.6)
Followed rehabilitation program in year prior to admission <u>n</u> (%)	10 (14.9)	12 (17.4)
Heart Rate (beats/minute)	91.0 (14.2)	95.6 (18.4)
<i>Arterial blood gas</i> <sup>#</sup> :	N=37	N=42
pH	7.44 (0.05)	7.43 (0.04)
pO <sub>2</sub> (mmHg)	70.7 (13.2)	67.3 (8.1)
pCO <sub>2</sub> (mmHg)	37.2 (6.2)	39.1 (5.3)
Saturation	94 (2.5)	94 (3.6)

† Charlson Comorbidity Index, 1= only COPD, higher score means more comorbidities; # only data of blood gas measurements in patients without oxygen supplement; LABA: long acting beta2 agonist

**Table 3**

Lung function testing at end of 3 month follow-up. Values represent mean (SD), unless stated otherwise.

	<u>Usual hospital care</u>	<u>Early assisted discharge</u>
<u>Postbronchodilator FEV<sub>1</sub> (litres)</u>	<u>1.25 (0.07)</u>	<u>1.21 (0.07)</u>
<u>% of predicted postbronchodilator FEV<sub>1</sub></u>	<u>50.29 (2.71)</u>	<u>45.20 (2.13)</u>
<u>GOLD stage I, n (%)</u>	<u>7 (10.3)</u>	<u>2 (2.9)</u>
<u>GOLD stage II, n (%)</u>	<u>22 (32.4)</u>	<u>23 (32.9)</u>
<u>GOLD stage III, n (%)</u>	<u>28 (41.2)</u>	<u>31 (44.3)</u>
<u>GOLD stage IV, n (%)</u>	<u>11 (16.2)</u>	<u>14 (20.0)</u>

Table 4 ~~Supplementary file 2~~ shows the unadjusted CCQ scores at the different measuring points. At T0 CCQ scores were 2.22 (0.97) for the usual hospital care group and 2.63 (1.06) for the early discharge group. Figure 2 shows the change in CCQ scores from T0, adjusted for baseline score. CCQ scores improved between T0 and T+4 days for the usual hospital care group, and were almost stable for the early assisted discharge group, but there was no significant difference between the groups at T+4 days (difference in mean change from T0 - 0.29, 95% CI ~~-0.03-0.61~~ to 0.61-0.03, p=0.078). At T+90 days, CCQ scores of both groups ~~scores~~ were slightly higher in comparison to T0. There was no difference between the groups at three months (difference in mean change from T0 -0.04, 95% CI ~~-0.40-0.48~~ to 0.49-0.41, p=0.858).

**Table 4**

Unadjusted mean (SD) CCQ total scores at each time of measurement by treatment group.

<u>Time of measurement</u>	<u>Usual hospital care</u>	<u>Early assisted discharge</u>
<u>T- 2 days</u>	<u>3.21 (1.07)</u>	<u>3.49 (1.07)</u>
<u>T0</u>	<u>2.22 (0.97)</u>	<u>2.63 (1.06)</u>

<u>T+ 4 days</u>	<u>2.00 (1.09)</u>	<u>2.55 (1.21)</u>
<u>T+ 90 days</u>	<u>2.41 (1.14)</u>	<u>2.70 (1.32)</u>

CCQ total score range is 0-6; 0 represents best possible score and 6 represents worst possible score

**Figure 2 CCQ total score, differences in mean change from baseline**

Treatment failed in five patients. One patient in the early discharge group needed readmission to the hospital because of deterioration of respiratory symptoms, before the end of the home treatment and 4 patients in the usual hospital care group required hospital admission beyond the 7 days that were stated in the protocol (2 because of deterioration of respiratory symptoms, 2 patients because of deterioration of general condition due to gastroenteritis caused by norovirus). This difference was not significant (OR early discharge group 0.27, 95% CI 0.026 – 2.70, p=0.263). Table 35 shows the number of readmissions during follow-up. Seventeen patients in each group had 1 or more readmission to the hospital of which 14 first readmissions were due to an exacerbation or other pulmonary indication (OR early discharge group 0.80, 95% CI 0.36 – 1.79, p=0.592). There was no difference in the number of readmissions per patient between the groups, or in the total number of readmissions in each group. There was no difference in time to first readmission between the two groups (HR early discharge group 0.77, 95% CI 0.39 to 1.53, p=0.461).

**Table 35** Readmissions during follow-up. Values are numbers of patients (%).

	Usual hospital care	Early assisted discharge
Patients with readmission	17 (25)	17 (24)
Patients with 1, 2 or ≥ 3 readmissions		

1 readmission	11	12
2 readmissions	4	3
3 or more readmissions	2	2
<u>Average (SD) time to first readmission in days</u>	<u>61 (36.5)</u>	<u>69 (33.8)</u>

No patient died during the hospital or home treatment, but 1 patient from each group died during follow-up. Cause of death was unknown in one case (patient died during sleep at home) and an acute abdomen in the other. Both were not related to the trial.

EQ-5D utility scores (SD) at T0 were 0.713 (0.22) for the usual hospital care group and 0.664 (0.26) for the early assisted discharge group. Table 46 shows the mean changes and mean difference in change from baseline of EQ-5D utility. In the usual hospital care group, mean utility scores improved from T0 to T+4 days and decreased to baseline at T+90 days. In the early assisted discharge group mean utility scores remained close to baseline. The mean change in utility scores on T+4 days was significant greater in the usual hospital care group. At T+90 days this difference between treatment groups had disappeared.

**Table 46** Mean changes and mean differences in change for EQ-5D.

		Mean change from baseline (SE)		Adjusted mean (95% CI) difference in change from baseline*	p value
Utility		Usual hospital care	Early assisted discharge	Usual care - early discharge	
	T+ 4 days†	0.051 (0.0261)	-0.005 (0.029)	0.0746 (0.010 to 0.139)	0.024
	T+ 90 days‡	-0.036 (0.0447)	0.008 (0.039)	-0.022 (-0.116 to 0.072)	0.639

\*Results from repeated measures analysis, adjusted for baseline value † hospital care N=57, early discharge N=61; ‡ hospital care N=47, early discharge N=54  
SE: Standard Error; 95% CI: 95% Confidence Interval

## Discussion

This is the first randomised controlled trial that investigated the effectiveness of early assisted discharge for COPD exacerbations with supervision at home by community nurses. In addition, this is the first evaluation of early discharge for this disease in the Dutch health care system. While patients' disease-specific health status as expressed in the mean CCQ score after seven days treatment tended to be somewhat better in the usual hospital care group, the difference was small, not clinically relevant and not statistically significant. After three months, the difference had disappeared. The same pattern was found in generic health-related quality of life measured with the EQ-5D, although this difference was statistically significant at the end of the supervised treatment. The difference had disappeared at the end of the 3-month follow up period. There was no difference in treatment failures, readmissions or mortality.

1  
2  
3 These study results confirm previously published positive results by Davison et al. [17] and  
4  
5 Nicholson et al. [18], but these two studies were either not randomised [17] or included a  
6  
7 small number of patients [18]. We found no significant difference in CCQ scores, which  
8  
9 corresponds with the findings of Davies et al. [9] and Hernandez et al. [16], who found no  
10  
11 differences in disease-specific quality of life measured with the St George's Respiratory  
12  
13 Questionnaire. Furthermore, our results are in line with those of earlier studies involving  
14  
15 specialised hospital-based nurses [9-12,15,16,24,25]. The readmission rate in our study was  
16  
17 25%, which is comparable to the 30% in previously published studies [9-11]. Characteristics  
18  
19 like age, smoking history and living situation of patients in our study were similar to those in  
20  
21 studies from the United Kingdom [9-12] and to that of a survey on hospital-at-home services  
22  
23 in British hospitals by Quantrill et al. [26].  
24  
25  
26  
27  
28

29  
30 Earlier studies did not measure the impact of hospital-at-home on generic health-related  
31  
32 quality of life. We found a significant difference between the two groups, in favour of usual  
33  
34 hospital care, at the end of the hospital and home treatment. This difference had disappeared  
35  
36 after three months. The utility scores are in line with O'Reilly et al. [27], but they found  
37  
38 much worse scores at admission than in our study, probably because we did not include  
39  
40 patients with more severe exacerbations. Utility and CCQ scores in both groups follow the  
41  
42 same pattern. The greater improvement in CCQ and EQ-5D scores of the usual hospital care  
43  
44 group at the end of the hospital treatment in comparison to the early discharge group may  
45  
46 reflect a true difference in recovery, in which case usual hospital care is the preferred  
47  
48 treatment. However, an alternative explanation could be that patients who were discharged  
49  
50 early were confronted with their symptoms and limitations earlier and more intensely when  
51  
52 they tried to pick up normal life at home. Furthermore, some patients have difficulties  
53  
54 viewing hospital care followed by early discharge as one treatment period [28]. Expecting to  
55  
56  
57  
58  
59  
60

1  
2  
3 be in a certain state at discharge, and experiencing this is not the case, might be expressed in  
4  
5 worse scores on the CCQ and the EQ-5D.  
6  
7

8  
9  
10 In our trial multiple hospitals participated with different socioeconomic and geographic  
11 characteristics, which makes it likely that our sample is representative of eligible patients. The  
12 percentage of admissions initially considered to be eligible for early discharge at admission  
13 was similar to that of previous studies ( $\pm 37\%$ ). Early discharge is possible when the  
14 exacerbation is the main problem and comorbidities are (relatively) stable. The percentage of  
15 patients living alone suggests that this is not an absolute reason for exclusion, provided that  
16 patients have a sufficiently functioning social support system. Still, 25% of screened patients  
17 were considered ineligible, because of living in a nursing home, overburden of informal  
18 caregiver(s) or living alone with insufficient social support. This suggests that social  
19 environment is an important factor when deciding for admission and (early) discharge.  
20  
21 Finally, 37% of screened patients was ineligible because of comorbidities.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Considering the very low number of treatment failures in the early discharge group it might be  
37 possible to relax the inclusion criteria and randomisation criteria. In our trial, criteria were  
38 applied very strictly for safety reasons, but more patients with comorbidities might be eligible  
39 in daily practice. Furthermore, the strict review and exclusion of patients at day 1 of  
40 admission (e.g. those treated with NIV), precluded patients from early discharge even if they  
41 had become eligible at day 3 of admission. Therefore, review of eligibility for early discharge  
42 should be performed after a few days of hospital treatment. Thirty percent of patients who  
43 consented to participate were not randomised because they showed insufficient recovery  
44 and/or were depending on oxygen supply. Unlike in the British hospital-at-home schemes,  
45 patients were not sent home with nebulisers or oxygen cylinders, unless these were already  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 part of their treatment. Extension of the treatment possibilities at home may enable early  
4  
5 discharge of patient with more severe disease. However, it would also require more expertise  
6  
7 of the nursing staff supervising patients at home, which might currently not be present in  
8  
9 community-based home care organisations. Future research should focus on determining  
10  
11 which treatments can be safely provided at home, which treatments require the supervision of  
12  
13 generic or specialised nurses and which criteria should be applied for selecting eligible  
14  
15 patients. In addition, a direct comparison between early discharge with generic and early  
16  
17 discharge with specialised nursing care would provide more information on which scheme is  
18  
19 most safe and effective.  
20  
21  
22  
23  
24

25 Our study has some limitations. Firstly, in total 139 patients were randomised, where a  
26  
27 number of 165 was calculated to be needed to detect a difference of 0.4 in CCQ change scores  
28  
29 between the two groups. A post-hoc power analysis with these 139 patients and the actual  
30  
31 variances in CCQ scores showed that the power to detect a difference in change from baseline  
32  
33 of 0.4 between the groups was 73% instead of 80%, which was aimed for. We believe that  
34  
35 this slight reduction in power does not have a substantial influence on our final results,  
36  
37 because the difference between the groups was only 0.29. It is highly unlikely that this  
38  
39 difference would have increased to the clinically relevant difference of 0.4 with an additional  
40  
41 26 patients. In previous randomised studies of early discharge in patients diagnosed with  
42  
43 COPD numbers varied between 25 and 222, and only 15 to 35% of admitted patients was  
44  
45 randomised [9-12,16,29]. Secondly, our study was not an equivalence trial, which would  
46  
47 determine best whether hospital care and early discharge care are equally effective. However,  
48  
49 in order to demonstrate equal effectiveness with CCQ score, over 500 patients would have  
50  
51 been needed, which is beyond what is attainable in this population. Thirdly, 16% of patients  
52  
53 dropped out after randomisation. However, comparison of patients who dropped out with  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 patients who completed the study only revealed more comorbidities for those who dropped  
4  
5 out. CCQ scores were not different. Fourthly, although our variable selection for the analyses  
6  
7 is justifiable, treatment centre could also be considered as an important covariate in the  
8  
9 analyses, based on the randomisation design of the study. However, adding treatment centre  
10  
11 as additional fixed factor to the analyses did not result in different outcomes in any of the  
12  
13 analyses. It was therefore omitted and the analyses remained unchanged.- Finally, due to the  
14  
15 nature of the intervention, patients and health care staff could not be blinded to the allocated  
16  
17 group.  
18  
19  
20

21  
22  
23 In conclusion, we found no significant short-term or long-term differences in outcomes  
24  
25 between early discharge and usual hospital care, except for generic health-related quality of  
26  
27 life at the end of treatment (T+4 days). Early assisted discharge with home visits by  
28  
29 community nurses can reduce length of hospital stay for a selected group of patients admitted  
30  
31 with a COPD exacerbation and is an alternative to usual hospital care. The decision to  
32  
33 implement early assisted discharge with community nursing does not only depend on the  
34  
35 results of the effectiveness analysis. Costs and cost-effectiveness evaluations are of high  
36  
37 importance as well. An economic evaluation is currently being performed and results will be  
38  
39 published separately.  
40  
41  
42  
43  
44

## 45 **Funding**

46  
47 The study was funded by the Netherlands Organisation for Health Research and Development  
48  
49 (ZonMw), grant application number 945-50-7730. The funder had no role in the design of the  
50  
51 study; the collection analysis and interpretation of the data; or the writing of the article and  
52  
53 the decision to submit the article for publication. All researchers were independent from the  
54  
55 funder.  
56  
57  
58  
59  
60

### Copyright/licence for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a **worldwide licence** to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.”

### Competing interests

“All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare that (1) LG, MR, OvS have had support from ZonMw for the submitted work; (2) CU, FS, MvV, MB, LvE have no relationships with companies that might have an interest in the submitted work in the previous 3 years; LG and MR have relationships (received grants to perform cost- and cost-effectiveness studies) from multiple pharmaceutical companies, OvS has relationships (consultancy) with Pfizer, Boehringer Ingelheim and Astra Zeneca that might have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or children have [specified] financial relationships that may be relevant to the submitted work; and (4) CU, LG, FS, MR, MvV, MB, LvE and OvS have no non-financial interests that may be relevant to the submitted work.”

## Contributors

CU was involved in patient recruitment, database management, administration of questionnaires, data analysis, data interpretation and wrote the manuscript. LG was involved in data analysis and data interpretation and preparation of the manuscript. FS was local coordinating physician and involved in data interpretation and preparation of the manuscript. MR designed the study and involved in data interpretation and preparation of the manuscript. MvV was local coordinating physician in the Atrium Medical Centre and involved in the preparation of the manuscript. MB and LvE were coordinators of the home care organisations and involved in the preparation of the manuscript. OvS designed the study and was involved in data interpretation and writing the manuscript. OvS is guarantor for the study. All researchers had access to all data.

## Acknowledgements

The authors thank all care professionals from the participating hospitals and home care organisations that made the trial and early assisted discharge possible: W. van Litsenburg (Catharina-hospital), A. Janssen (Catharina-hospital), W. Seezink (Atrium Medical Centre), B. van de Pas (Máxima Medical Centre), A. van der Pouw (Rijnstate Hospital) and P. de Laat (TweeSteden Hospital) who performed patient recruitment; R. Eijsermans who coordinated the home care visits in the Tilburg region; D. DeMunck (Máxima Medical Centre), J. Retera (TweeSteden Hospital) and P. de Bruijn (Rijnstate Hospital) who were responsible pulmonologists in the participating hospitals. We thank K. van der Meer, research assistant, for her assistance in the data input.

## Data sharing

No additional data available

## References


1. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007;370:741-750.
2. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;176:532-555.
3. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J* 2006;27:397-412.
4. Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;157:1418-1422.
5. Donaldson GC, Seemungal TA, Bhowmik A et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002;57:847-852.
6. Esteban C, Quintana JM, Moraza J et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. *Respir Med* 2009;103:1201-1208.
7. Toy EL, Gallagher KF, Stanley EL et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. *COPD* 2010;7:214-228.
8. Jordan RE, Hawker JI, Ayres JG et al. Effect of social factors on winter hospital admission for respiratory disease: a case-control study of older people in the UK. *Br J Gen Pract* 2008;58:400-402.

- 1  
2  
3 9. Davies L, Wilkinson M, Bonner S et al. "Hospital at home" versus hospital care in  
4 patients with exacerbations of chronic obstructive pulmonary disease: prospective  
5 randomised controlled trial. *BMJ* 2000;321:1265-1268.  
6  
7
- 8  
9  
10 10. Cotton MM, Bucknall CE, Dagg KD et al. Early discharge for patients with  
11 exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.  
12 *Thorax* 2000;55:902-906.  
13  
14
- 15  
16 11. Skwarska E, Cohen G, Skwarski KM et al. Randomized controlled trial of supported  
17 discharge in patients with exacerbations of chronic obstructive pulmonary disease.  
18 *Thorax* 2000;55:907-912.  
19  
20
- 21  
22 12. Ojoo JC, Moon T, McGlone S et al. Patients' and carers' preferences in two models of  
23 care for acute exacerbations of COPD: results of a randomised controlled trial. *Thorax*  
24 2002;57:167-169.  
25  
26
- 27  
28 13. British Thoracic Society. Intermediate care--Hospital-at-Home in chronic obstructive  
29 pulmonary disease: British Thoracic Society guideline. *Thorax* 2007;62:200-210.  
30  
31
- 32  
33 14. Diaz LS, Gonzalez LF, Gomez Mendieta MA et al. [Evaluation of a home  
34 hospitalization program in patients with exacerbations of chronic obstructive  
35 pulmonary disease]. *Arch Bronconeumol* 2005;41:5-10.  
36  
37
- 38  
39 15. Grivil JH, Al-Rawas OA, Cotton MM et al. Home treatment of exacerbations of  
40 chronic obstructive pulmonary disease by an acute respiratory assessment service.  
41 *Lancet* 1998;351:1853-1855.  
42  
43
- 44  
45 16. Hernandez C, Casas A, Escarrabill J et al. Home hospitalisation of exacerbated chronic  
46 obstructive pulmonary disease patients. *Eur Respir J* 2003;21:58-67.  
47  
48
- 49  
50 17. Davison AG, Monaghan M, Brown D et al. Hospital at home for chronic obstructive  
51 pulmonary disease: an integrated hospital and community based generic intermediate  
52 care service for prevention and early discharge. *Chron Respir Dis* 2006;3:181-185.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 18. Nicholson C, Bowler S, Jackson C et al. Cost comparison of hospital- and home-based  
4 treatment models for acute chronic obstructive pulmonary disease. *Aust Health Rev*  
5 2001;24:181-187.  
6  
7
- 8  
9  
10 19. Utens CM, Goossens LM, Smeenk FW et al. Effectiveness and cost-effectiveness of  
11 early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the  
12 design of a randomised controlled trial. *BMC Public Health* 2010;10:618  
13  
14
- 15 20. van der Molen T, Willemse BW, Schokker S et al. Development, validity and  
16 responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes*  
17 2003;1:13  
18  
19
- 20 21. Kocks JW, Tuinenga MG, Uil SM et al. Health status measurement in COPD: the  
21 minimal clinically important difference of the clinical COPD questionnaire. *Respir*  
22 *Res* 2006;7:62  
23  
24
- 25 22. Lamers LM, McDonnell J, Stalmeier PF et al. The Dutch tariff: results and arguments  
26 for an effective design for national EQ-5D valuation studies. *Health Econ*  
27 2006;15:1121-1132.  
28  
29
- 30 23. Rothman KJ, Greenland S, Lash TL. *Modern Epidemiology* (3rd edition).  
31 Philadelphia: Lippincott Williams & Wilkins 2008.  
32  
33
- 34 24. Ansari K, Shamssain M, Farrow M et al. Hospital-at-home care for exacerbations of  
35 chronic obstructive pulmonary disease: an observational cohort study of patients  
36 managed in hospital or by nurse practitioners in the community. *Chron Respir Dis*  
37 2009;6:69-74.  
38  
39
- 40 25. Sala E, Alegre L, Carrera M et al. Supported discharge shortens hospital stay in  
41 patients hospitalized because of an exacerbation of COPD. *Eur Respir J* 2001;17:1138-  
42 1142.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


- 1  
2  
3 26. Quantrill SJ, Lowe D, Hosker HS et al. Survey of early discharge schemes from the  
4 2003 UK National COPD Audit. *Respir Med* 2007;101:1026-1031.  
5  
6  
7 27. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with  
8 COPD exacerbation managed in hospital. *Int J Clin Pract* 2007;61:1112-1120.  
9  
10  
11 28. Clarke A, Sohanpal R, Wilson G et al. Patients' perceptions of early supported  
12 discharge for chronic obstructive pulmonary disease: a qualitative study. *Qual Saf*  
13 *Health Care* 2010;19:95-98.  
14  
15  
16 29. Aimonino RN, Tibaldi V, Leff B et al. Substitutive "hospital at home" versus inpatient  
17 care for elderly patients with exacerbations of chronic obstructive pulmonary disease:  
18 a prospective randomized, controlled trial. *J Am Geriatr Soc* 2008;56:493-500.  
19  
20  
21  
22  
23  
24  
25 30. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic  
26 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*  
27 1987;40:373-383  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





\*Not asked to participate because of logistical reasons (e.g. no study staff available or patient not admitted to respiratory ward)

114x93mm (300 x 300 DPI)



Error bars represent standard errors. P values are based on repeated measures analysis, adjusted for baseline value.

\*Number of patients at T+4 days that completed questionnaire that produced valid total CCQ; \*\*number of patients at T+90 days that completed questionnaire that produced valid total CCQ score.

NOTE: for interpretation reasons the sign of the CCQ has been reversed. Positive change in CCQ scores represents improvement of patients condition, which is a decrease in CCQ scores.

60x34mm (300 x 300 DPI)

Review only



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	5-6
	2b	Specific objectives or hypotheses	5-6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6-7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	n/a
Participants	4a	Eligibility criteria for participants	6-7 & table 1
	4b	Settings and locations where the data were collected	6-7
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	8-9 & reference 19
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9
	6b	Any changes to trial outcomes after the trial commenced, with reasons	n/a
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n/a
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7

1				
2	Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	18
3				
4		11b	If relevant, description of the similarity of interventions	8-9
5	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9-10
6		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	n/a
7				
8				
9	<b>Results</b>			
10	Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	10 & fig 1
11		13b	For each group, losses and exclusions after randomisation, together with reasons	10 & fig 1
12	Recruitment	14a	Dates defining the periods of recruitment and follow-up	6 & 10
13		14b	Why the trial ended or was stopped	n/a
14	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	table 2
15	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	All tables and figures with results
16				
17	Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	13-14 Tables & figures
18		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	n/a
19	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	n/a
20				
21	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	n/a
22				
23	<b>Discussion</b>			
24	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	18
25	Generalisability	21	Generalisability (external validity, applicability) of the trial findings	15 to 18
26	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	15 to 18
27				
28	<b>Other information</b>			
29	Registration	23	Registration number and name of trial registry	abstract
30	Protocol	24	Where the full trial protocol can be accessed, if available	Reference 19
31	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	19
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44	CONSORT 2010 checklist			
45				
46				
47				
48				
49				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

For peer review only